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ABSTRACT 
 
MARK A. WALLET: MerTK Mediates Immune Homeostasis: Effects upon Dendritic 
Cell Function and Type 1 Diabetes 
(Under the direction of Roland Tisch, PhD) 
 
    The receptor tyrosine kinase Mer (MerTK) is expressed by dendritic cells (DC) in mice. 
The heretofore undefined role of MerTK in DC was investigated in two major studies.  First, 
the role of MerTK in the inhibition of DC activation by apoptotic cells was investigated. It 
was found that apoptotic cells inhibited DC activation by bacterial lipopolysaccharide or 
CD40 crosslinking via MerTK. Inhibition of DC was characterized by blockade of IL-12p70 
secretion, co-stimulatory molecule expression and stimulation of CD4+ and CD8+ T cells. 
The MerTK ligand growth arrest specific factor-6 (Gas6) was expressed on the surface of 
apoptotic cells, and Gas6 was essential for the inhibitory effects of apoptotic cells upon DC. 
Non-obese diabetic (NOD) mice, lacking MerTK expression (NOD.MerTKKD/KD), 
demonstrated aberrant expansion of type 1 CD4+ and CD8+ T cell effectors in response to 
apoptotic cell death in vivo. Furthermore, NOD.MerTKKD/KD mice expressing a diabetogenic 
T cell receptor transgene, developed diabetes at an accelerated rate and a greater frequency 
than mice expressing MerTK. These findings support a role for MerTK in peripheral immune 
homeostasis. 
    Secondly, the impact of MerTK-deficiency in NOD mice was investigated. 
NOD.MerTKKD/KD mice were protected from diabetes onset and protection was due to lack of 
self-specific type 1 CD4+ and CD8+ T cell effectors. Thymic selection was enhanced in 
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NOD.MerTKKD/KD mice resulting in deletion of pathogenic, autoreactive T cells. The change 
in thymic selection efficiency was mediated by bone marrow-derived cells and was likely 
due to dysregulation of thymic DC. These data indicate that MerTK mediates 
immunoregulation of DC in both the periphery and the thymus.
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CHAPTER I 
INTRODUCTION 
 
Type 1 Diabetes 
    Type 1 diabetes (T1D) is a chronic disease which manifests as dysregulation of glucose 
metabolism due to the loss of insulin-producing pancreatic β cells within the Islets of 
Langerhans. T1D is classified as either type 1A or type 1B. Type 1B diabetes is a rare 
disease characterized by the idiopathic loss of β cell function (Abiru et al., 2002). The more 
common form of T1D is Type 1A which is caused by autoimmune destruction of the β cells 
(Tisch and McDevitt, 1996). In both types of T1D, insulin deficiency and resultant 
hyperglycemia induce many chronic pathologies including diabetic nephropathy, diabetic 
retinopathy (Fong et al., 2004) and cardiovascular disease (Daneman, 2006). Treatment of 
T1D is currently achieved through subcutaneous administration of various insulin 
preparations. The use of fast-acting and long-acting insulins  are implemented to better 
control blood glucose levels (Daneman, 2006) as it has been found that poor glycemic 
control is associated with increased frequency of complications (1993; 1994). 
    To date, prevention of T1D in at-risk individuals or reversal of T1D in patients has been 
largely ineffective. Replacement of β cell mass has been attempted through transplantation of 
the whole pancreas or purified-islets. Typically, whole pancreas and kidney transplants are 
combined and this approach has been somewhat effective in reversal of T1D. The risks,
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 however, of such major surgery and lifelong immune suppression are high (Sutherland, 
2003; Sutherland et al., 2001). In contrast, islet transplantation carries a much lower risk, 
although short- and long-term insulin independence is rare due to allogeneic and auto-
immune rejection of donor β cells (Balamurugan et al., 2006). Advancements in transplant 
efficacy will require a greater understanding of the underlying defects which contribute to 
autoimmunity in T1D patients. 
 
 
T1D Inheritance 
    T1D is a complex, multifactoral disease with genetic and environmental factors 
contributing to susceptibility and induction (Tisch and McDevitt, 1996). Extensive study of 
human T1D patients and animal models, such as the non-obese diabetic (NOD) mouse, has 
identified several genetic loci which confer susceptibility or resistance to T1D (Anjos and 
Polychronakos, 2004). Additionally, evidence suggests that environmental factors play a key 
role in T1D development as indicated by the discordant rate of T1D onset among identical 
twins. Although monozygotic twins of type 1 diabetics develop diabetes at a significantly 
greater frequency than dizygotic twin or non-twin siblings of type 1 diabetics, the frequency 
of onset for monozygotic twins is less than 25%. (Redondo et al., 1999). This suggests that 
environmental factors contribute to β cell autoimmunity. Indeed, evidence indicates a 
potential role for viral infections, including Coxsackievirus B virus and rubella virus 
(Coulson et al., 2002; Honeyman et al., 2000), in triggering and/or exacerbating T1D (Filippi 
and von Herrath, 2005). Multiple factors have made it difficult to conclusively implicate viral 
infections or other environmental factors, such as diet and various toxins, in T1D 
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development.  T1D patients are, for the most part, a heterogeneous population with 
significant genetic variability. Furthermore, subtle environmental influences, possibly 
occurring years before T1D diagnosis, are difficult to track. 
    Inheritance of T1D in humans and rodents is highly complex and, to date, not well 
understood. The most important locus for T1D inheritance in humans is the human leukocyte 
antigen (HLA) gene cluster. Specific alleles of HLA class II molecules confer 40-50% of 
T1D susceptibility (Anjos and Polychronakos, 2004). T1D is most often associated with 
specific HLA-DQ and HLA-DR β chain alleles which lack an aspartic acid residue at amino 
acid position 57. Substitution of alanine, valine or serine at position 57 results in altered 
peptide binding by those HLA class II molecules, which in turn is proposed to promote the 
development of pathogenic, β cell-specific T cells (Tisch and McDevitt, 1996). Inheritance of 
T1D in the NOD mouse is similarly conferred mostly by a major histocompatibility complex 
(MHC) class II I-A allele (Wicker et al., 1995). The I-Ag7 MHC β chain molecule carries an 
amino acid substitution at position 57 similar to diabetogenic human HLA-DQ and HLA-DR 
alleles (Acha-Orbea and McDevitt, 1987; Todd et al., 1987).  
    In addition to HLA and MHC class II, many genetic loci in humans and mice have been 
associated with T1D inheritance. To date, only 2 additional human genes have been 
identified among the many candidate genes within the susceptibility loci. Allelic variants of 
cytotoxic T lymphocyte antigen 4 (CTLA-4) and alterations in the variable number of 
tandem repeats (VNTR) upstream of the insulin gene have been directly linked to T1D 
susceptibility (Bain et al., 1992; Julier et al., 1991; Marron et al., 2000). The vast majority of 
causal genes within T1D susceptibility loci in humans and NOD mice remain to be 
identified. 
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T1D Pathology 
Autoantibody production in T1D 
    The autoimmune process, within the islets of pre-diabetic and diabetic humans, remains 
ill-defined. Tissue samples from T1D patients are rare, and as such, much of our 
understanding of T1D in humans comes from analysis of autoantibodies and autoreactive T 
cells detected in peripheral blood. The presence of circulating β cell-reactive antibodies is not 
considered to be a factor in islet destruction, however, these antibodies serve as a predictor 
for T1D onset in at-risk individuals (Lieberman and DiLorenzo, 2003). Islet cell antibodies 
(ICA) were first observed within islets of diabetic human pancreatic tissue sections (Bottazzo 
et al., 1974). Since then, many studies have identified predictive autoantibodies in human 
diabetics including antibodies specific for insulin (Lieberman and DiLorenzo, 2003; Palmer 
et al., 1983; Yu et al., 2000), glutamic acid decarboxylase 65 (GAD65) (Baekkeskov et al., 
1990; Hagopian et al., 1993; Lieberman and DiLorenzo, 2003) and insulinoma-associated 
protein 2 (IA-2) (Lampasona et al., 1996; Lan et al., 1996; Lieberman and DiLorenzo, 2003) 
The presence of insulin, GAD65 and IA-2 antibodies provide good predictive value for onset 
of T1D in at-risk individuals. Among siblings of type 1 diabetics, 39% of those with 2 of the 
3 antibodies develop T1D within 3 years and greater than 90% of those with all 3 antibodies 
develop T1D within 3 years (Verge et al., 1996). NOD mice also produce anti-insulin 
antibodies (Yu et al., 2000), but not significant anti-GAD65 or IA-2 antibodies (Bonifacio et 
al., 2001; Lieberman and DiLorenzo, 2003).  
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Autoimmune destruction of pancreatic islets  
    While autoantibodies provide measurable diagnostic markers for predicting T1D onset, 
actual β cell destruction is carried out by CD4+ and CD8+ T cells. Little is known about the 
local cellular events which contribute to human pre-diabetes and eventual development of 
overt diabetes. Pancreatic tissue is usually only available from post-T1D autopsy samples. 
Thus, animal models such as the NOD mouse have been used to gain an understanding of 
early disease pathology. Questions of relevance have been raised for the NOD mouse as it 
relates to the human disease. Careful and extensive analyses, however, have shown that 
murine and human T1D bear many similarities. Even if therapeutic approaches may not 
directly translate from mouse to human, many discoveries of T1D pathology were first 
described in NOD mice (Shoda et al., 2005).  
    T1D pathology begins at approximately 3 weeks of age in NOD mice. Islets become 
surrounded by a population of macrophages and dendritic cells (DC), followed rapidly by 
CD4+ and CD8+ T cells (Jansen et al., 1994). This early infiltration of islets is known as peri-
insulitis (Figure 1.1C). Although β cell destruction is dependent on macrophages, DC and B 
cells, CD4+ and CD8+ T cells are the key mediators of disease progression (Kay et al., 1997; 
Wong and Janeway, 1999). Type 1 CD4+ T cells, which produce IFNγ, promote β cell 
destruction, while TH2 CD4+ T cells, which produce IL-4, IL-5 and IL-10, suppress T1D 
development (Anderson and Bluestone, 2005; Delovitch and Singh, 1997; Rabinovitch, 
1994). Expansion of type 1 CD4+ T cells is induced by the pro-inflammatory cytokine IL-12 
(Trembleau et al., 1995), which is produced by macrophages and DC within the islets and/or 
pancreatic lymph node (PLN). Additionally, pathogenic type 1 CD8 T cells are required for 
the development of diabetes (Lieberman and DiLorenzo, 2003; Serreze and Leiter, 2001). 
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This is supported by evidence that Class I MHC genes are associated with T1D susceptibility 
(Pociot and McDermott, 2002; Serreze and Leiter, 2001). 
    β cell autoimmunity in NOD mice progresses in relatively well-defined stages or 
“checkpoints” (Andre et al., 1996). Prior to 3 weeks of age, no islet pathology can be 
detected. At three weeks of age the first checkpoint of T1D is reached. Checkpoint 1 is 
characterized by infiltration of the islets by macrophages, DC, B cells and T cells (Andre et 
al., 1996; Bergman and Haskins, 1994; Kaufman et al., 1993; Tisch et al., 1993) (Figure 
1.1A-E). Insulitis continues from approximately 3 to 12 weeks of age, however the majority 
of β cell mass remains intact and mice remain diabetes-free. Even severe insulitis may persist 
without sufficient β cell destruction to induce overt diabetes (Andre et al., 1996). Checkpoint 
2 is characterized by a qualitative change whereby “benign” insulitis transitions to an 
“aggressive” or pathogenic form of insulitis resulting in massive β cell destruction and 
eventual development of overt diabetes (Andre et al., 1996). Complete β cell destruction 
following Checkpoint 2 is dependent upon expansion of type 1 CD4+ and CD8+ T cells 
within the islets. (Andre et al., 1996; Liblau et al., 1995; Rabinovitch, 1994) At this point, 
from approximately 12-30 weeks of age, NOD mice develop overt diabetes, marked by 
hyperglycemia and glucosuria (Figure 1.1A). The exact mechanisms responsible for 
progression from Checkpoint 1 to Checkpoint 2 are not well understood, however, it is likely 
that DC play a role in this process due to three key characteristics: 1. DC are present within 
the islets throughout both checkpoints (Charre et al., 2002; Jansen et al., 1994; Nikolic et al., 
2005), 2. DC efficiently process self-antigens for presentation via MHC and prime T cell 
expansion (Kubach et al., 2005; Steinman et al., 2005), and 3. DC produce IL-12p70 which is 
essential for differentiation of type 1 CD4+ T cells and CD8+ CTL effectors (Trembleau et 
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al., 1995; Trinchieri, 2003; Trinchieri et al., 1993; Trinchieri et al., 1992). The effects of DC 
dysregulation upon progression from Checkpoint 1 to Checkpoint 2 will be addressed in 
Chapter 2. 
    Autoreactive CD4+ and CD8+ T cells that recognize β cell antigens can be found in 
peripheral blood samples of human T1D patients and NOD mice. Several CD4+ T cell 
specificities for GAD65 and insulin epitopes have been identified (Lieberman and 
DiLorenzo, 2003). The pathogenicity of these T cells was proven when adoptive transfer of 
insulin-specific CD4+ T cell clones was found to accelerate T1D in NOD mice (Daniel et al., 
1995). Additionally, autoreactive CD8+ T cells, recognizing epitopes from GAD65 and 
insulin, can be found in diabetic humans and NOD mice (Lieberman and DiLorenzo, 2003). 
NOD mice also present with CD8+ T cells which recognize islet-specific glucose-6-
phosphatase catalytic subunit related protein (IGRP) (Lieberman et al., 2003). IGRP-specific 
CD8+ T cells can be found at high frequencies, up to 40% of CD8+ T cells, in the islets of 
NOD mice (Anderson et al., 1999). 
    Type 1 CD4+ and CD8+ T cells are clearly the most important mediators of β cell 
destruction in T1D. These effectors are, however, dependent upon antigen presenting cells 
(APC) to locally present antigen and provide inflammatory cytokines. Both B cells (Serreze 
and Leiter, 2001) and DC (Nikolic et al., 2005) are essential for T1D progression. Indeed DC 
play key roles in maintenance of self-tolerance in healthy individuals, and defects in DC 
function may contribute to autoimmune diseases, including T1D (Yoon and Jun, 2005). 
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The Role of DC in T1D 
DC background 
    In humans and mice DC are identified by expression of the cell-surface marker CD11c. 
DC are further differentiated into conventional DC (cDC) and plasmacytoid DC (pDC). 
Murine cDC consist of CD11c+ CD11b+ CD8α- and CD11c+ CD11b- CD8α+ subsets (Vremec 
et al., 1992), which may be derived from either myeloid or lymphoid progenitor cells (Manz 
et al., 2001). Murine pDC are identified by expression of CD11c and B220. Similar to cDC, 
pDC can arise from both myeloid and lymphoid lineages (Karsunky et al., 2005; Wang and 
Liu, 2004). DC are versatile APC, capable of performing many immune functions. Most 
notably, DC can prime naïve T cells and induce T cell differentiation and clonal expansion 
(Kubach et al., 2005; Steinman et al., 2005). DC also phagocytose different types of antigen 
including particulate antigens, pathogenic agents (i.e. bacteria) necrotic tissue and apoptotic 
cells (Rossi and Young, 2005). The diverse nature of antigenic targets captured by DC 
requires flexibility in DC responses. It would be undesirable, for example, to have equivalent 
immune responses to bacteria and self apoptotic cells. It is due to this duality in function that 
DC are capable of inducing immunity to pathogens, as well as maintaining self-tolerance 
(Kubach et al., 2005). Indeed, aberrant DC development and function is characteristic of 
multiple autoimmune diseases including T1D (Yoon and Jun, 2005), systemic lupus 
erythemetosus (SLE) and rheumatoid arthritis (RA) (Banchereau et al., 2004; Hardin, 2005).  
    The normal role of DC is to serve as sentinels, scanning for signs of infection. Upon 
encounter and phagocytosis of infectious agents such as bacteria or viruses, DC undergo 
functional maturation characterized by up-regulation of co-stimulatory molecules (CD40, 
CD80 and CD86), production of pro-inflammatory cytokines (TNFα, IL-12p70, IL-1α and 
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IL-1β) and up-regulation of the chemokine receptor CCR7 (Hardin, 2005; Kubach et al., 
2005; Rossi and Young, 2005). Expression of CCR7 mediates DC homing to lymphatic 
endothelial cells in response to CCL21 and eventually to T cell rich areas of secondary 
lymphoid tissues in response to CCL19 (Cravens and Lipsky, 2002). Mature DC are well-
equipped to prime naïve CD4+ T cells, inducing differentiation to a type 1 phenotype. It is 
type 1 CD4+ T cells which are integral to β cell destruction during the development of T1D 
(Cantor and Haskins, 2005; Tisch and McDevitt, 1996). The breakdown of self-tolerance in 
diabetic humans and animal models is poorly understood, however, many studies provide 
evidence that atypical DC function is, in part, responsible. 
 
 
DC mediate early and late events of T1D pathogenesis 
    As indicated above, the earliest histological pathology of T1D is the development of peri-
insulitis. Due to the lack of human tissue samples from recent onset diabetics or pre-diabetic 
patients, little is know about the initiating events of insulitis in human diabetes. There is, 
however, much evidence from NOD mice to implicate DC in the initiation of β cell 
destruction. Infiltration of islets by DC and macrophages begins as early as birth in NOD 
mice. One day old NOD mice demonstrate increased frequency of CD11c+ DC within the 
pancreas relative to non-autoimmune mice (Charre et al., 2002). DC become localized to 
pancreatic islets by 3 weeks of age, before the arrival of lymphocytes. DC expressing high 
levels of MHC class II, CD80 and CD86 continue to accumulate at parainsular vessels, found 
adjacent to the islets, and within the islets from 7 to 13 weeks of age. During this period, 
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accumulation of T cells accompanies DC infiltration and destructive insulitis ensues 
(Shinomiya et al., 2000) (Figure 1.1E).  
    The events triggering DC accumulation within the islets remain largely undefined, but 
some evidence has suggested that a wave of physiological cell death in murine islets may 
promote DC trafficking. This so-called “ripple” of cell death, at 12 days of age, is believed to 
be a normal component of tissue remodeling, however, it may lead to DC activation and β 
cell antigen capture in diabetes-prone animals (Trudeau et al., 2000; Turley et al., 2003). In 
this model, CD11c+CD11b+, and to a lesser extent CD11c+CD8α+ DC acquire antigens from 
dead cells in the pancreas and traffic to the PLN to stimulate CD4+ and CD8+ T cells (Turley 
et al., 2003). Notably, humans undergo a similar wave of β cell death at birth, which may 
also provide access of β cell antigens to the immune system (Kassem et al., 2000).  
     The specific mechanisms that induce DC maturation within the islets are not completely 
understood, however, evidence exists which implicates CD40 signaling in this process. Mice 
expressing CD40 ligand (CD40L, CD154) on β cells demonstrate DC activation in islets and 
PLN. This DC activation, along with T cell priming eventually leads to the development of 
destructive insulitis and diabetes in otherwise non-autoimmune mice (Haase et al., 2004). 
The presence of DC within islets between 4 and 8 weeks of age also correlates with a 
transient phase of hyperinsulinemia in NOD mice. Interestingly, DC associate preferentially 
with abnormally large, hyperinsulinemic islets during this period (Rosmalen et al., 2000). In 
fact, when NOD DC and purified islets are co-cultured in vitro, insulin production is 
significantly increased, whereas non-autoimmune C57BL/6 DC do not induce 
hyperinsulinemia (Durant et al., 2002). The mechanism responsible for DC-induced insulin 
production is not understood, however, the phenomenon may contribute to the disease 
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process by placing β cells under increased stress, which in turn can lead to cell death 
(Kassem et al., 2000). Additionally, there is some evidence that female sex hormones 
contribute to hyperinsulinemia and DC infiltration of NOD mouse islets through either 
modulation of DC function or effects mediated directly upon the islets (Rosmalen et al., 
2001).  
    DC, as well as macrophages, within early pancreatic infiltrates produce significant 
amounts of the pro-inflammatory cytokine TNFα, prior to the arrival of lymphocytes. 
Notably, TNFα treatment of neonatal NOD mice induces DC maturation and enhances the 
frequency of CD11c+CD11b+ DC relative to CD11c+CD8α+ DC in the islets. Development of 
diabetes is accelerated in TNFα-treated animals, whereas TNFα depletion completely inhibits 
diabetes development (Lee et al., 2005). These findings suggest a crucial role for DC and 
TNFα production in the development of destructive insulitis. 
    DC, it seems, are not only necessary for the development of insulitis, but also for 
maintenance of insulitic lesions throughout disease. For example, DC depletion correlates 
with reversal of lymphocytic infiltration of the islets (Nikolic et al., 2005), providing strong 
evidence that DC are essential for priming autoreactive lymphocytes within the target tissue 
and/or the pancreatic lymph node.  
 
 
DC Defects Associated With T1D 
    DC are clearly involved in the pathogenesis of autoimmune diabetes at many stages of the 
disease. It is unlikely, however, that a single defect in DC biology is wholly responsible for 
the complicated processes required for the onset of T1D. Many differences in DC 
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development and activation (described below) have been observed in NOD mice and human 
diabetics. 
 
 
DC of the NOD mouse 
    Studies detailing the DC populations of NOD mice have indicated phenotypic and 
functional differences in DC in vivo and in cultures of bone marrow-derived DC (BMDC). 
These findings have frequently been contradictory, possibly due to varying conditions of DC 
culture. 
    Several analyses of DC in NOD mice have focused upon culture of DC from bone marrow 
(BM)-derived precursor cells by addition of growth factors. It was found that BMDC cultures 
from NOD mice produced significantly increased yields of DC relative to non-autoimmune 
mice, when cultured with GM-CSF and IL-4 (Steptoe et al., 2002). In contrast, another group 
found that NOD BM cultures preferentially differentiate into MHC class II negative, CD11c+ 
macrophage-like cells, with low yield of mature DC (Nikolic et al., 2004). These experiments 
utilized BM cells cultured with GM-CSF but not IL-4. Additionally, a study which utilized 
titrated doses of GM-CSF and IL-4 found that, under all conditions tested NOD BM 
differentiated mostly into granulocytes with decreased yields of DC (Morin et al., 2003). 
Finally, when recombinant murine GM-CSF and IL-4 were encoded by baculovirus infecting 
insect cells, the supernates induced DC differentiation, albeit at a lower frequency in NOD 
versus non-autoimmune mice (Prasad and Goodnow, 2002b). Despite variability in the 
results, it is clear that NOD DC develop aberrantly compared to DC cultured from non-
autoimmune mice. 
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    In addition to varying yields of DC from BM cultures, studies of NOD BMDC 
demonstrate alterations in function. Multiple studies have found that BMDC and ex vivo-
derived DC from NOD mice demonstrate increased activity of the transcription factor NF-κB 
(Poligone et al., 2002; Weaver et al., 2001; Wheat et al., 2004). NF-κB hyper-activation 
induces increased CD40 and CD80 expression (Wheat et al., 2004), and elevated IL-12p70 
secretion relative to non-autoimmune DC (Weaver et al., 2001). NF-κB hyperactivity in 
NOD DC also results in an enhanced capacity to stimulate T cells (Marleau and Singh, 2002; 
Poligone et al., 2002). In contrast, several studies have found that NOD DC demonstrate 
impaired maturation (Peng et al., 2003a), decreased MHC class II expression (Strid et al., 
2001), poor stimulation of allogeneic lymphocytes (Nikolic et al., 2004), and ineffective 
presentation of soluble peptide antigen to T cells (Strid et al., 2001). One consistent finding 
among investigators is the relative decrease in frequency of CD11c+CD8α+ DC and increased 
frequency of CD11c+CD11b+ DC (O'Keeffe et al., 2005; Prasad and Goodnow, 2002a). 
Together, these findings highlight the complexity of T1D, even when utilizing inbred strains 
of mice with essentially identical genetic backgrounds.  
 
 
DC of at-risk and T1D patients 
    Investigation of DC populations in humans has provided similarly variable results. It has 
been reported that diabetic patients possess phenotypically similar DC, when  compared to 
healthy individuals (Summers et al., 2003). Additionally, the maturation and T cell 
stimulating capacity of DC from recent-onset T1D patients was similar to that of healthy-
donors (Zacher et al., 2002). Meanwhile, other findings indicate that DC of diabetics 
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demonstrate impaired maturation (Angelini et al., 2005), decreased inflammatory cytokine 
production (Skarsvik et al., 2004) and a decreased T cell stimulatory capacity relative to 
healthy individuals (Angelini et al., 2005; Skarsvik et al., 2004). Another study found 
increased DC numbers, increased MHC class II expression by DC and increased production 
of IFNγ by DC from at-risk and recent-onset T1D patients (Peng et al., 2003b). Clearly, the 
nature of DC maturation and function in diabetic patients requires further analysis. The 
important role of DC in insulitis and β cell destruction, as well as the observed DC variability 
in mice and humans, indicate that multiple functional differences in DC likely contribute to 
T1D development. 
 
 
Immunoregulation of DC by Apoptotic Cells 
    DC activation is typically described in response to pathogens. Unperturbed environments 
foster maintenance of immature DC, while microbial pathogens induce activation and 
maturation of DC (Banchereau and Steinman, 1998).  This representation of DC life cycle 
accurately represents a portion of immune regulation, but the model fails to address the 
activity of DC under homeostatic conditions. Multicellular organisms constantly harbor a 
mixed balance of viable, apoptotic and necrotic tissues. The continual exposure to self-
antigen necessitates that DC maturation and effector function be regulated to maintain 
immunological tolerance (Wallet et al., 2005). 
    The clearance of apoptotic cells in vivo is carried out by multiple phagocytes including 
macrophages, neutrophils and DC. In the case of DC, it is only immature cells that are 
capable of phagocytosing apoptotic cells (Albert et al., 1998). Binding and ingestion of 
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apoptotic cells by immature DC is mediated by a group of receptors including 
phosphatidylserine receptor (PSR) (Li et al., 2003), αVβ5 integrin, CD36 (Albert et al., 1998) 
and the receptor tyrosine kinase MerTK (Cohen et al., 2002).  
    In general, when DC encounter apoptotic cells, a non-inflammatory and tolergenic 
phenotype typical of immature DC is induced (Steinman et al., 2000). For example DC 
which are pretreated with apoptotic cells exhibit a reduced capacity to produce IL-12p70 
upon stimulation with bacterial endotoxin (Stuart et al., 2002). Immature DC treated with 
apoptotic cells also exhibit an impaired capacity to stimulate T cells. Notably, 
lipopolysaccharide (LPS) treatment is unable to overcome the “tolergenic” phenotype, 
indicating the effect of apoptotic cells is long-lasting and relatively stable (Takahashi and 
Kobayashi, 2003). As a result, activation of DC carrying the remnants of apoptotic cells is 
effectively prevented. In addition to inducing an immature DC phenotype, apoptotic cells 
have been reported to induce the expression of IL-6 and IL-12p40, and therefore further 
enhance the tolergenic function of the DC (Takahashi and Kobayashi, 2003). Apoptotic cell-
induced IL-6 secretion by DC functions in an autocrine manner to block further maturation of 
DC (Figure 1.2). For example, activation of STAT3 following IL-6 pretreatment blocks LPS-
induced up-regulation of CD80, CD86, CD40 and MHCII on DC, thereby reducing the T cell 
stimulatory capacity of the DC (Park et al., 2004). Additionally, secretion of high levels of 
IL-12p40 results in formation of IL-12p40 homodimers, which competitively inhibit IL-
12p70 binding to the IL-12 receptor on T cells (Takahashi and Kobayashi, 2003; Wang et al., 
1999). Consequently, differentiation of naïve CD4+ T cells into type 1 cells is suppressed 
(Figure 1.2).  
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    Phagocytosis of apoptotic cells by DC affects cross-presentation of self-antigens to CD8+ 
T cells. Employing human DC and apoptotic versus necrotic 293 tumor cells, the importance 
of the mode of death of the phagocytosed cells was initially defined. Necrotic but not 
apoptotic 293 cells induced DC maturation based on up-regulation of CD83 and DC-LAMP. 
Furthermore, a robust mixed lymphocyte reaction (MLR) was induced by pulsing DC with 
necrotic but not apoptotic allogeneic splenocytes  (Sauter et al., 2000). Furthermore, 
apoptotic cells modulate DC effector function in vivo. Injection of apoptotic splenocytes 
coupled with trinitrophenol into mice blocked in vitro recall responses to the hapten. 
Importantly, CD11c+CD8α+ DC were identified as the critical effectors for inducing the 
immune tolerance to apoptotic cell-derived antigens (Ferguson et al., 2002).  
    These data and work by others support a role for DC in maintaining immunological 
homeostasis (Basu et al., 2000; Stuart et al., 2002; Xu et al., 2004). In contrast, necrotic cells 
typical of microbial infections induce DC activation and maturation, and subsequent 
immunity. This balance in DC reactivity allows the peripheral immune system to continually 
monitor tissues for signs of death and mount the appropriate response. The importance of DC 
in clearance of apoptotic cells and the maintenance of immune homeostasis is highlighted in 
autoimmune diseases such as SLE. While not wholly causal for SLE, failure to effectively 
clear apoptotic cells contributes to the severity of disease (Gaipl et al., 2004). 
    Recent work by our group has been performed to describe the signaling mechanisms 
responsible for apoptotic cell-induced DC tolerance. Initial results show that apoptotic cells 
block pro-inflammatory stimuli, such as TLR and CD40 signaling through inhibition of NF-
κB activation (unpublished data P.S., M.W. and R.T.). 
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Thymic Selection 
Thymic selection is a complex process whereby thymocytes expressing high-avidity, self-
specific T cell receptor (TCR) or non-functional TCR are removed. Much evidence exists to 
implicate failures of thymic selection in the development of T1D in NOD mice. 
 
 
Positive selection 
    Typical thymic structure includes a well defined central medullary region and a 
surrounding cortex. Thymocyte populations include CD4- CD8- (double-negative, DN) cells, 
CD4+CD8+ (double-positive, DP) cells and single positive (SP) CD4+ and CD8+ T cells (Liu, 
2006). Positive selection occurs when DP cells expressing a functional TCR encounter 
cortical thymic epithelial cells (CTE). CTE express MHC class I and MHC class II molecules 
which present self peptides. TCR which recognize self-MHC-peptide complexes mediate 
survival signals to DP cells. Meanwhile, DP cells expressing a TCR that fails to recognize 
self-MHC-peptide die by neglect (Hogquist et al., 2005; Starr et al., 2003; von Boehmer, 
1994). Positively selected cells then proceed to the corticomedullary junction and medulla for 
negative selection. 
 
 
Negative selection 
    Negative selection is the process whereby DP cells demonstrating relatively high-avidity 
recognition of self-MHC-peptide are deleted. Medullary thymic epithelial (MTE) cells 
express a multitude of peripheral tissue self-antigens under the control of the transcription 
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factor Aire (Anderson et al., 2002). Presentation of self antigen epitopes by MTE allows 
deletion of high-avidity self-specific DP cells. 
    Additionally, the murine thymus possesses three distinct populations of DC. pDC provide 
no observable role in thymic selection and instead, likely act as sentinels for infection within 
the thymus. CD11c+ CD11b+ CD8α- and CD11c+ CD11b- CD8α+ cDC subsets are also found 
in the thymic medulla (Liu, 2006; Wu and Shortman, 2005). Currently, it is unclear which 
cDC mediate negative selection, however, evidence strongly suggests that one or both 
subsets play a direct role in self-tolerance through negative selection (Anderson et al., 1998; 
Brocker, 1997; Matzinger and Guerder, 1989).  
 
 
Thymic selection in the NOD mouse 
    NOD defects in thymic positive and negative selection have been associated with the 
presence of pathogenic, high-avidity CD4+ and CD8+ T cells which mediate β cell 
destruction (Kwon et al., 2005). Two distinct failures of positive selection in NOD mice 
contribute to T1D progression. First, CTE of NOD mice appear to be inefficient in inducing 
CD4+CD25+ Treg development, which may in turn promote differentiation of autoreactive T 
effectors in the periphery (Thomas-Vaslin et al., 1997). Secondly, high expression of ERK 
and JNK by DP cells alters the outcome of low affinity TCR/MHC-peptide interactions in the 
thymus. Therefore, low affinity TCR-bearing DP cells which would typically die by neglect, 
go on to become pathogenic CD8+ T cell effectors (Kwon et al., 2005).  
    It has been proposed that negative selection in NOD thymi is inefficient, in part due to 
abnormal medulla and cortex organization (Naquet et al., 1999; Rosmalen et al., 2002; 
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Savino et al., 1991). Additionally, expression of I-Ag7 MHC class II in NOD mice and 
diabetogenic HLA-DR and HLA-DQ alleles in humans has been proposed to contribute to 
inefficient negative selection (Rosmalen et al., 2002). For example, studies suggest that I-Ag7 
binds self-peptides poorly resulting in decreased presentation of self-peptides required for 
deletion of high-avidity DP cells (Moustakas et al., 2000; Stratmann et al., 2000). 
Interestingly, it has been found that thymic expression of the β cell tissue antigen insulin is 
significantly decreased in NOD mice relative to other strains of mice (Brimnes et al., 2002), 
which may result in inefficient deletion of insulin-specific T cells.  
 
 
MerTK 
Background 
    MerTK is a 984 amino acid transmembrane protein (Figure 1.3) that is expressed by 
various cell types. MerTK (c-mer, NYK) belongs to a family of tyrosine kinases that includes 
Axl and Tyro3. All three receptors play roles in spermatogenesis (Chan et al., 2000; Lu et al., 
1999), platelet function (Chen et al., 2004; Gould et al., 2005) and neuronal development 
(Prieto et al., 2000). Sequence analysis indicates that MerTK shares homology with the 
chicken proto-oncogene c-eyk and the chicken tumor retrovirus oncogene v-eyk (Graham et 
al., 1995). Similarly, human MerTK shares homology with v-eyk and thus both human and 
murine MerTK have been considered as putative proto-oncogenes (Graham et al., 1995; 
Graham et al., 1994). MerTK expression has been detected in neoplastic B and T cell lines 
(Graham et al., 1994), however, MerTK signaling in transfected tumor cells does not induce 
proliferation. Instead, cell cycle arrest and structural differentiation of tumor cells is induced 
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(Guttridge et al., 2002; Wu et al., 2004). Interestingly, transgene-induced overexpression of 
MerTK in hematopoetic cells of mice leads to lymphoblastic leukemia/lymphoma 
development (Keating et al., 2006).  
    The majority of MerTK studies in mice and humans have focused upon functional roles in 
phagocytosis of apoptotic cells and innate immunity. MerTK is expressed by retinal pigment 
epithelial cells (RPE) of humans, mice and rats (Duncan et al., 2003; Feng et al., 2002; Gal et 
al., 2000; Hall et al., 2003; Hall et al., 2005; Hall et al., 2001; McHenry et al., 2004; Zhao et 
al., 2006). MerTK expression by RPE is essential for efficient phagocytosis of apoptotic 
outer segment cells (OS) of photoreceptors in the eye (Hall et al., 2001). Lack of MerTK 
expression in mice and humans leads to accumulation of apoptotic debris, progressive retinal 
dystrophy and blindness (Gal et al., 2000{Duncan, 2003 #262; McHenry et al., 2004; Zhao et 
al., 2006).   
 
 
The role of MerTK in immune cells 
    Expression of MerTK among leukocytes is predominantly limited to cells of monocytic 
lineage (Graham et al., 1995). In particular, expression of MerTK by macrophages is 
essential for phagocytosis of apoptotic cells. (Cohen et al., 2002; Scott et al., 2001; Wu et al., 
2005). The MerTK ligand growth arrest specific factor-6 (Gas6) (Chen et al., 1997; Nagata et 
al., 1996) is an opsonin of phosphatidylserine (PS). Apoptotic cells that expose PS on their 
outer cytoplasmic membrane become coated with Gas6. Notably, phagocytosis of apoptotic 
OS cells by RPE is dependent on recognition of Gas6 by MerTK (Hall et al., 2003; Hall et 
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al., 2001). Therefore, it is likely that Gas6 also mediates phagocytosis of apoptotic cells by 
macrophages. 
    MerTK, Axl and Tyro3 play critical roles in peripheral immune regulation of mice. 
Macrophages lacking MerTK exhibit a hyperactive phenotype, marked by increased 
activation of NF-κB and secretion of TNFα (Camenisch et al., 1999; Li et al., 2006). 
Furthermore, mice lacking expression of MerTK, Axl and Tyro3 develop a severe 
lymphoproliferative disorder and systemic autoimmunity (Lu and Lemke, 2001). MerTK 
expression has been reported for DC, NK cells and NKT cells in mice. (Behrens et al., 2003). 
Unlike macrophages, the capacity of DC to phagocytose apoptotic cells is unaffected by the 
lack of MerTK expression (Behrens et al., 2003). In fact, the role of MerTK seems to be 
primarily to regulate DC activation and maturation. Recent results have indicated that 
apoptotic cells suppress activation of DC and inhibit NF-κB activation via MerTK 
(unpublished data P.S., M.W. and R.T.). The impact of MerTK on DC function will be 
addressed in Chapter 2 and Chapter 3.  
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Figure 1.1 
 
 
 
 
Insulitis of the NOD mouse. (A) Diabetes progression in the NOD mouse begins with the 
early presence of DC within the pancreas. Throughout insulitis, DC are essential to the 
autoimmune process. (B-D, black arrows) Mononuclear immune cells enter the islets via 
para-insular vessels. (C, red arrows) Early islet infiltration is marked by a ring of 
mononuclear cells which surround the islet, known as peri-insulitis. (D) As the disease 
progresses, intra-insulitis develops and islets are destroyed. (E) Insulitis consists of many cell 
types, however DC (E, green) and CD4+ T cells (E, red) are critical to destruction of insulin-
producing β cells (E, blue). 
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Figure 1.2 
 
 
 
 
Apoptotic cells induce immunoregulation and tolerance induction through DC. DC 
scavenge tissues for microbes and dying tissue. Apoptotic cells induce phosphatidylinositol 
3-kinase (PI3K)-dependent signaling resulting in inhibition of NF-κB translocation and co-
stimulatory molecule (CD80/86) expression. Production of IL-6, TGF-β and IL-12p40 ensue. 
IL-12p40 homdimers inhibit the effects of IL-12p70 upon T lymphocytes, effectively 
inhibiting type 1 induction. Apoptotic cells induce a lasting inhibitory effect which renders 
DC refractory to LPS induced stimulation of type 1 lymphocytes. (Reproduced with 
permission from Wallet MA, Sen P, Tisch R. Immunoregulation of dendritic cells. Clin Med 
Res 2005;3:166-175. Copyright 2005 Marshfield Clinic. All rights reserved). 
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Figure 1.3 
 
 
 
 
MerTK protein structure. MerTK is a 984 amino acid transmembrane protein. The 
extracellular domain consists of two immunoglobulin like domains (Ig) and two fibronectin 
type III domains (FN3). A transmembrane region spans the plasma membrane and the 
cytoplasmic tail consists of tyrosine kinase domains.  
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CHAPTER II 
THE ROLE OF MERTK IN APOPTOTIC CELL-INDUCED 
SELF-TOLERANCE 
Mark A. Wallet, Pradip Sen, Ralph Flores, Zuoan Yi, Yingsu Huang, Clayton E. Matthews, 
H. Shelton Earp, Glenn Matsushima, and Roland Tisch. 
 
Abstract 
    Self-antigens expressed by apoptotic cells may become targets for autoimmunity. 
Tolerance to these self-antigens is established partly by an ill-defined capacity of apoptotic 
cells to inhibit the activation and function of antigen presenting cells such as dendritic cells 
(DC). We present evidence that the receptor tyrosine kinase Mer (MerTK) has a key role in 
mediating apoptotic cell-induced inhibition of DC. Pretreatment of DC prepared from 
nonobese diabetic (NOD) mice with apoptotic cells blocked IL-12p70 secretion and up-
regulation of co-stimulatory molecule expression following stimulation. In contrast, NOD 
DC treated with a blocking anti-MerTK antibody or lacking MerTK expression 
(NOD.MerTKKD/KD) were resistant to apoptotic cell-induced inhibition. Apoptotic cell 
pretreatment failed to inhibit the capacity of NOD.MerTKKD/KD but not NOD DC to stimulate 
CD4+ and CD8+ T cells in vitro. Similarly, diabetogenic CD4+ T cells adoptively transferred 
into NOD.MerTKKD/KD mice in which β cell apoptosis was induced, exhibited increased 
expansion and differentiation into type 1 T effectors. Finally, the development of 
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autoimmune diabetes was exacerbated in NOD.MerTKKD/KD versus NOD mice expressing a 
diabetogenic transgenic T cell receptor. These findings demonstrate that MerTK plays a 
critical role in apoptotic cell-induced self-tolerance. 
 
 
Introduction 
    The processes of tissue remodeling, wound healing and removal of damaged cells rely on 
cell death by apoptosis. Cells undergoing apoptosis undergo a highly ordered process 
characterized by cell shrinkage, retention of organelles, nuclear chromatin condensation and 
fragmentation, and redistribution of phosphatidylserine (PS) on the plasma membrane (Fadok 
et al., 1992; Kerr et al., 1972). Under homeostatic conditions, APC such as macrophages and 
DC recognize and ingest apoptotic cells using a variety of receptors including the PS 
receptor, scavenger receptor-A (SR-A), CD36 and αvβ5 integrin (Wallet et al., 2005). In this 
way, the breakdown and release of potentially immunogenic self-antigens by apoptotic cells 
is avoided (Savill et al., 1993). Indeed, inefficient clearance of apoptotic cells has been linked 
to autoimmunity (Gaipl et al., 2004).  
    The binding and ingestion of apoptotic cells also results in immunoregulation of APC to 
further promote self-tolerance. For instance, activation of macrophages is blocked and TGF-β 
secretion induced by apoptotic cell pretreatment (Huynh et al., 2002; Reidy and Wright, 
2003). Similarly, immature DC become refractory to subsequent stimulation upon encounter 
with apoptotic cells, and maintain a “tolergenic” phenotype characterized by low levels of 
MHC, CD40, CD80 and CD86 expression and the lack of proinflammatory cytokine 
secretion (Morelli et al., 2003; Voll et al., 1997).  Consequently, these DC are unable to 
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effectively stimulate naïve T cells or promote type 1 CD4+ T cell differentiation. In the non-
obese diabetic (NOD) mouse model of autoimmune diabetes, induction of limited apoptosis 
of pancreatic β cells prevents progression of the diabetogenic response. This correlates with 
the establishment of tolergenic DC, which in turn elicit immunoregulatory T cells (Hugues et 
al., 2002). The key receptors expressed by DC and the relative contribution of these receptors 
in mediating the inhibitory effects of apoptotic cells, however, remain ill defined.  
    A family of receptor tyrosine kinases (RTKs) consisting of Axl, Tyro3 and Mer (MerTK) 
has been reported to regulate homeostatic activation of macrophages and DC. Mice lacking 
all three RTKs exhibit systemic autoimmunity marked by highly activated APC in vivo (Lu 
and Lemke, 2001). The mechanism(s) by which Axl, Tyro3 and MerTK regulate APC 
activation is unclear. MerTK, which also is expressed by NKT cells, certain epithelial cell 
types and reproductive tissues, is required for efficient phagocytosis of apoptotic cells by 
peritoneal macrophages (Cohen et al., 2002; Scott et al., 2001). Lupus-like symptoms 
detected in aging C57BL/6 mice in which MerTK expression is blocked due to insertion of a 
neomycin cassette in the kinase domain of the mertk gene (MerTKKD) are believed to be, in 
part, the result of inefficient clearance of apoptotic cells by macrophages. Investigation of 
retinal pigment epithelial cells (RPE) has also shown that engulfment of apoptotic outer 
segments shed from the photoreceptor is mediated by MerTK via recognition of growth 
arrest-specific protein-6 (Gas6) and protein S (Behrens et al., 2003) (Nandrot et al., 2004). 
Gas6 is ubiquitously expressed and in addition to binding MerTK, also serves as a PS 
opsonin mediating phagocytosis of apoptotic cells (Ishimoto et al., 2000).   
    In view of its function as a receptor for apoptotic cells by macrophages and RPE, we 
investigated a role for MerTK in immunoregulation of DC by apoptotic cells. Data is 
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presented demonstrating that MerTKKD/KD DC are no longer sensitive to the inhibitory effects 
of apoptotic cells, and that T1D is exacerbated in MerTKKD/KD NOD mice 
(NOD.MerTKKD/KD) expressing a β cell-specific transgenic TCR.   
 
 
Results 
Apoptotic cells inhibit DC activation and maturation via MerTK 
    Previous studies have demonstrated that apoptotic cells regulate DC activation and 
maturation (Chen et al., 2004b). Furthermore, MerTK has been shown to mediate apoptotic 
cell phagocytosis by macrophages and RPE. Accordingly, a role for MerTK in apoptotic cell-
induced inhibition of DC was investigated using NOD.MerTKKD/KD mice as a source of DC 
lacking MerTK expression. The NOD.MerTKKD/KD line of mice used in this study contained 
a 17 cM segment of 129/Ola chromosome 2 harboring the MerTKKD mutation that was 
introgressed 11 backcross generations (see Materials and Methods). 
    Pretreatment of NOD mouse bone marrow-derived DC (BMDC) with apoptotic cells for 3 
hrs completely inhibited LPS-stimulated IL-12p70 secretion that was readily detected in 
LPS-only treated BMDC (Figure 2.1A). In contrast, NOD.MerTKKD/KD BMDC secreted 
similar levels of IL-12p70 in response to LPS, regardless of apoptotic cell pretreatment 
(Figure 2.1A). Apoptotic cells also blocked LPS-stimulated IL-12p70 secretion by splenic 
DC (sDC) prepared from NOD but not NOD.MerTKKD/KD mice (Figure 2.1B). Notably, in 
MerTK-expressing CD11c+CD8α+ and CD11c+CD11b+ NOD sDC (Figure 2.2B, C), LPS-
stimulated expression of intracellular IL-12 was inhibited by apoptotic cell pretreatment 
(Figure 2.1C). 
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    In order to rule out strain-specific variations in the NOD mouse that could be contributing 
to the effects of apoptotic cells upon DC, non-autoimmune BALB/c DC were analyzed. As 
demonstrated in Figure 2.6A, apoptotic cells also induced inhibition of IL-12p70 production 
in BALB/c BMDC. In addition, BMDC from B6.MerTKKD/KD mice, like NOD.MerTKKD/KD 
DC, were no longer sensitive to the inhibitory effects of apoptotic cells (unpublished data 
P.S., M.W. and R.T.).  
    Analogous to IL-12 production, up-regulation of CD40, CD80, and CD86 expression was 
inhibited by apoptotic cell pretreatment of NOD BMDC stimulated with LPS (Figure 2.1D). 
In contrast, apoptotic cell pretreatment had no significant effect on the induction of co-
stimulatory molecule expression by LPS-stimulated NOD.MerTKKD/KD BMDC (Figure 
2.1D). 
    To rule out the possibility that apoptotic cell-induced inhibition was selective to LPS 
stimulation, NOD versus NOD.MerTKKD/KD BMDC treated with anti-CD40 antibody (Ab) 
were compared. Crosslinking with anti-CD40 Ab induced IL-12p70 secretion by NOD 
BMDC that was significantly reduced by apoptotic cell pretreatment (p<10-3) (Figure 2.1E). 
On the other hand, anti-CD40 Ab-induced IL-12p70 secretion was unaffected by apoptotic 
cell pretreatment of NOD.MerTKKD/KD BMDC (Figure 2.1E). Stimulation of NOD BMDC 
with anti-CD40 Ab also induced up regulation of CD40 expression. CD40 induction was 
inhibited by co-culture of DC with apoptotic cells before CD40 crosslinking (Figure 2.1F). 
CD40 expression by NOD.MerTKKD/KD BMDC was not inhibited by apoptotic cells (Figure 
2.1F).  
    The effect of apoptotic cell pretreatment on the capacity of NOD and NOD.MerTKKD/KD 
BMDC to stimulate CD4+ and CD8+ T cells in vitro was investigated. For this purpose, CD4+ 
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and CD8+ T cells were isolated from the spleens of NOD.BDC2.5 (Haskins et al., 1989; Katz 
et al., 1993) and NOD.CL4 (Morgan et al., 1996) TCR transgenic mice, respectively. In the 
absence of apoptotic cells, peptide-pulsed NOD and NOD.MerTKKD/KD BMDC stimulated 
BDC2.5 CD4+ and CL4 CD8+ T cells to similar levels based on IL-2 secretion (Figure 2.3A, 
B). However, apoptotic cell pretreatment significantly inhibited the capacity of peptide-
pulsed NOD BMDC to stimulate BDC2.5 CD4+ (p<10-3) and CL4 CD8+ (p<10-3) T cells 
(Figure 2.3A, B). In contrast, apoptotic cell pretreatment failed to inhibit peptide-pulsed 
NOD.MerTKKD/KD BMDC stimulation of BDC2.5 CD4+ and CL4 CD8+ T cells (Figure 2.3A, 
B). 
    Finally, to ensure that the lack of sensitivity of NOD.MerTKKD/KD DC to apoptotic cell 
pretreatment was not due to an artifact of DC developing in the absence of MerTK 
expression, the effect of a blocking anti-MerTK polyclonal Ab on NOD BMDC was 
assessed. Importantly, the blocking function of the polyclonal Ab was verified by 
demonstrating that phosphorylation of MerTK induced by apoptotic cells was effectively 
inhibited by treating NOD DC with anti-MerTK Ab but not an isotype control Ab (Figure 
2.4). Despite apoptotic cell pretreatment, LPS-stimulated IL-12p70 secretion (Figure 2.5A) 
and up-regulation of co-stimulatory molecule expression (Figure 2.5B) were readily detected 
in NOD BMDC incubated with anti-MerTK Ab. Furthermore, apoptotic cells failed to inhibit 
stimulation of BDC2.5 CD4+ (Figure 2.5C) and CL4 CD8+ (Figure 2.5D) T cells by NOD 
BMDC incubated with anti-MerTK but not the isotype control Ab.  Together these findings 
demonstrate that apoptotic cell-induced inhibition of activation, maturation and effector 
function of BMDC or sDC is dependent on MerTK expression/activation. 
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The MerTK ligand Gas6 is expressed by apoptotic cells and is necessary for apoptotic 
cell-induced inhibition of DC 
    An effort was made to define the ligand recognized by MerTK on the surface of AC. Gas6 
and Protein S are two known ligands of MerTK (Hall et al., 2005), although other, yet to be 
identified, ligands have been proposed. Initial work indicated that Protein S, which is found 
in serum, was not associated with apoptotic cells used in our experiments. RTPCR analysis 
was performed and did not detect Protein S gene expression in apoptotic cells. Additionally, 
the inhibitory properties of apoptotic cells on NOD BMDC were not affected when serum-
free medium was used in the experiments (unpublished data P.S., M.W. and R.T.). Next, 
whether Gas6 functions as a MerTK ligand was determined. Gas6 has been reported to bind 
PS (Wu et al., 2006) and therefore should be exposed on the outer leaflet of apoptotic cells. A 
VAD-FMK-FITC conjugate was used to identify apoptotic cells in cultures of γ-irradiated 
thymocytes, in addition to apoptotic thymocytes prepared directly from the thymus. Flow 
cytometric analysis demonstrated that Gas6 was detected on the surface of apoptotic 
thymocytes induced by γ-irradiation, and apoptotic thymocytes found normally within the 
thymus (Figure 2.7A). Furthermore, Gas6 protein expression was induced, as determined by 
Western Blot, in irradiated thymocytes cultured under serum-free conditions (Figure 2.7C) 
    A direct role for Gas6 in AC-mediated inhibition of DC was determined by using a 
polyclonal anti-Gas6 Ab. Pretreatment of apoptotic cells with anti-Gas6 but not an isotype 
control Ab effectively blocked the capacity of apoptotic cells to inhibit LPS-stimulated IL-
12p70 secretion by NOD BMDC (Figure 2.7C). These results demonstrate that Gas6 surface 
expression is induced upon apoptotic cells, and is necessary for MerTK-mediated inhibition 
of DC. 
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MerTK-mediated recognition of apoptotic cells induces in vivo tolerance to self antigens 
    The lack of sensitivity of peripheral MerTKKD/KD DC to AC-induced inhibition in vivo 
would be expected to promote autoimmunity. To initially test this hypothesis, NOD.BDC2.5 
mice expressing the β cell-specific BDC2.5 TCR transgene were bred with 
NOD.MerTKKD/KD mice, and the development of diabetes monitored in female mice that 
expressed wild-type levels of MerTK (NOD.BDC2.5) or no MerTK 
(NOD.MerTKKD/KD.BDC2.5). Only 10% (1/10) of NOD.BDC2.5 female mice developed 
diabetes (Figure 2.8), consistent with frequencies reported for other NOD.BDC2.5 colonies. 
In contrast, the age of diabetes onset was earlier (11 weeks vs. 21 weeks) and the frequency 
of diabetes (65% vs. 10%) was markedly increased in NOD.MerTKKD/KD.BDC2.5 versus 
NOD.BDC2.5 female mice (Figure 2.8).  
    The above results suggested that in NOD.MerTKKD/KD.BDC2.5 mice, apoptotic β cells 
failed to inhibit DC activation and/or maturation leading to enhanced activation of BDC2.5 
CD4+ T cells, and exacerbation of disease progression. To further investigate this hypothesis, 
a model system was established examining the reactivity of naïve BDC2.5 CD4+ T cells 
transferred into 4 week-old NOD versus NOD.MerTKKD/KD recipients in which β cell 
apoptosis was synchronized by treatment with a single dose of streptozotocin (STZ). This 
approach was necessary since analysis of NOD.BDC2.5 and NOD.MerTKKD/KD.BDC2.5 
mice is problematic due to heavy islet infiltration at an early age (i.e. by 3 wks of age) and 
the fact that β cell apoptosis is not synchronized. STZ has been used extensively to induce β 
cell apoptosis, and treatment of 4 wk old NOD female mice with a single low dose of STZ 
prevents diabetes due in part to induction of tolergenic DC (Hugues et al., 2002). NOD or 
NOD.MerTKKD/KD mice received a single i.p. injection of 120 mg/kg of STZ or citrate saline 
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as a vehicle control. Gas6 was readily detected on the surface of apoptotic β cells following 
STZ treatment (Figure 2.9). CFSE labeled BDC2.5 CD4+ T cells were adoptively transferred, 
and 3 days later proliferation was measured in the draining pancreatic lymph nodes. Only 
limited BDC2.5 CD4+ T cell proliferation was detected in NOD recipients treated with STZ 
or citrate saline (Figure 2.10). Similarly, no significant BDC2.5 CD4+ T cell proliferation 
was observed in citrate saline treated NOD.MerTKKD/KD recipients (Figure 2.10). In marked 
contrast, BDC2.5 CD4+ T cells exhibited significant proliferation in NOD.MerTKKD/KD mice 
treated with STZ (Figure 2.10).  
    The total number of CFSE+ BDC2.5 CD4+ T cells in the pancreatic lymph nodes of citrate 
saline-treated NOD and NOD.MerTKKD/KD mice was similar (Table 2.1). In contrast, 
significant increases in the total number (11-fold) of CFSE+ BDC2.5 CD4+ T cells and the 
frequency (16-fold) of IFNγ+ CFSE+ BDC2.5 CD4+ T cells were detected in STZ-treated 
NOD.MerTKKD/KD versus NOD recipients (Table 2.1). These data suggest that MerTK is 
essential for in vivo tolerance to apoptotic cells and that apoptotic cell death in the absence of 
MerTK expression on DC leads to aberrant T cell stimulation. Experiments are ongoing to 
address the specific cell types which are responsible for excessive T cell priming in MerTK-
deficient mice. 
 
 
Discussion 
    Apoptotic cells provide a continuous source of self-antigen which can be ingested, 
processed and presented by DC. Mechanisms are in place to ensure that DC do not initiate 
immunity to these self-antigens. This study was undertaken to gain further insight into 
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apoptotic cell-induced immunoregulation of DC. MerTK has an established role in 
phagocytosis of apoptotic cells by macrophages (Cohen et al., 2002; Scott et al., 2001; Wu et 
al., 2005) and RPE (Hall et al., 2001). In addition, MerTK and its family members, Axl and 
Tyro3, mediate immunoregulation in mice (Camenisch et al., 1999; Lu and Lemke, 2001). In 
light of these facts, a potential role for MerTK in immunoregulation of DC by apoptotic cells 
was investigated. Analysis of BMDC as well as ex vivo-derived CD11c+ CD11b+ and 
CD11c+ CD8α+ sDC indicated an essential role for MerTK in apoptotic cell-induced 
immunoregulation. Pretreatment of BMDC or sDC with apoptotic cells induced inhibition of 
DC activation in response to LPS or CD40 ligation. Typically, LPS and CD40 ligation induce 
IL-12p70 secretion and expression of co-stimulatory molecules. Apoptotic cells inhibited 
LPS- or CD40-induced IL-12p70 secretion and co-stimulatory molecule expression by NOD 
DC but not by MerTK-deficient NOD DC (Figure 2.1). The defect observed in 
NOD.MerTKKD/KD DC was not due to alterations in DC development as demonstrated by 
blockade of MerTK upon NOD DC with a specific polyclonal Ab. Pre-treatment of NOD DC 
with anti-MerTK Ab prevented the inhibitory effects of apoptotic cells similar to MerTK-
deficient DC (Figure 2.5). 
    Apoptotic cell-induced immunoregulation of DC also inhibited the capacity of DC to 
stimulate CD4+ and CD8+ T cells. Again, MerTK-deficient DC were not inhibited by 
apoptotic cells and continued to stimulate T cells (Figure 2.3). This is not surprising, as DC 
mediated T cell stimulation requires co-stimulatory molecule expression and positive 
feedback activation of DC through CD40, both of which are inhibited by apoptotic cells. 
    Importantly, DC from NOD or NOD.MerTKKD/KD mice functioned similarly in the 
absence of apoptotic cells. Levels of IL-12 production, co-stimulatory molecule expression 
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and T cell stimulation were similar regardless of MerTK expression (Figure 2.1). Only when 
pre-treated with apoptotic cells was there a marked difference in activation and maturation 
between MerTK-expressing versus MerTK-deficient DC. Thus, the primary role of MerTK 
in DC is recognition of apoptotic cells and subsequent transduction of inhibitory signals. For 
example, MerTK was dispensable for efficient phagocytosis of apoptotic cells by DC (Figure 
2.11) but not for macrophages and RPE.  
    Importantly, the effects observed in NOD DC are not strain-specific. DC from BALB/c 
mice were similarly immunoregulated by apoptotic cells via MerTK (Figure 2.6). In addition, 
MerTK-deficient C57BL/6 DC were resistant to apoptotic cell-induced inhibition similar to 
NOD.MerTKKD/KD mice (unpublished data P.S., M.W. and R.T.).  
    Previous studies have shown that Gas6 is a ligand bound by MerTK (Chen et al., 1997; 
Nagata et al., 1996) and Gas6 is essential for MerTK-mediated phagocytosis of apoptotic OS 
cells by RPE (Gould et al., 2005; Hall et al., 2003; Hall et al., 2001; Naquet et al., 1999). 
Additionally, Gas6 induces platelet activation via MerTK (Chen et al., 2004a; Gould et al., 
2005). These findings, along with a well-established role for Gas6 as a PS opsonin (Nakano 
et al., 1997), led to investigation of Gas6 as the ligand for MerTK in apoptotic cell-induced 
inhibition of DC. Gas6 was expressed on the surface of apoptotic thymocytes (Figure 2.7A) 
as well as apoptotic β cells (Figure 2.9). Antibody blockade of Gas6 prevented the 
immunoregulatory effects of apoptotic cells upon DC (Figure 2.7C). These findings clearly 
demonstrate that MerTK binds Gas6 on the surface of apoptotic cells triggering signaling 
events which inhibit subsequent DC activation. 
    The impact of MerTK-deficiency on DC immunoregulation led to the prediction that 
peripheral T cell-tolerance would be defective in mice lacking MerTK. The NOD.BDC2.5 
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mouse provides an ideal model to test this hypothesis in vivo. Although NOD.BDC2.5 mice 
exhibit significant insulitis, only a relatively low frequency (10-20%) of mice progress 
beyond Checkpoint 1 and develop overt diabetes (Andre et al., 1996; Katz et al., 1995; 
Ohashi et al., 1993). Notably, NOD.MerTKKD/KD.BDC2.5 mice developed accelerated onset 
and increased frequency of diabetes compared to NOD.BDC2.5 mice (Figure 2.8). This 
finding supports a role for MerTK in regulating T cell-mediated autoimmunity in vivo. 
However, the data only provides indirect evidence that MerTK-mediated immunoregulation 
in vivo is induced by apoptotic cells. To directly address this issue, a model of apoptotic cell-
induced immune tolerance was utilized. Previous work had demonstrated that induction of β 
cell apoptosis with STZ results in DC-mediated immune tolerance and protection from T1D 
(Hugues et al., 2002). In this model, tolergenic DC are established which, in turn, promote 
differentiation of immunoregulatory T cells. Our findings suggest that MerTK plays a key 
role in establishing these tolergenic DC. For example, STZ treatment of NOD.MerTKKD/KD 
mice induced increased expansion and type 1 differentiation of BDC2.5 CD4+ T compared to 
similarly treated NOD mice (Figure 2.10, Table 2.1). Importantly, differences in BDC2.5 
CD4+ T cell proliferation and differentiation were not the result of aberrant induction of β cell 
apoptosis or clearance of apoptotic β cells, which were similar between STZ-treated NOD 
and NOD.MerTKKD/KD mice (data not shown).   
    We propose that DC lacking MerTK expression become activated upon encountering 
apoptotic β cells and, in turn, promote a pro-inflammatory response. The latter is 
characterized by differentiation of pathogenic T effectors which drive the progression of β 
cell destruction and the development of diabetes.  
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    One highly intriguing issue centers on the location of mertk within a T1D-susceptibility 
locus in mice and humans. It is possible that allelic variants of mertk encode proteins with 
differing immunoregulatory properties. Thus, activation status of DC may be altered, 
resulting in different levels of autoimmune susceptibility. Analysis of mertk alleles in mice is 
discussed further in Chapter 3.  
    Interpretation of MerTK-deficiency and its impact upon autoimmunity is not a simple task. 
Dysregulation of DC function impacts not just peripheral immunity but also thymic selection, 
due to the presence of DC within the thymus. Interestingly, MerTK-deficient NOD mice are 
protected from spontaneous diabetes due to enhanced thymic negative selection and deletion 
of pathogenic autoreactive T cells (Chapter 3). This result contrasts with the findings in 
NOD.MerTKKD/KD.BDC2.5 mice, which are prone to T1D, illustrating that alterations in DC 
function in the periphery and thymus can have dramatically different outcomes.  
    Together, the data presented here support a novel mechanism of self-tolerance. Apoptotic 
cells expressing surface Gas6 induce phosphorylation of MerTK on DC. MerTK 
phosphorylation leads to a signaling cascade which inhibits NF-κB-mediated DC activation 
(unpublished data, P.S., M.W. and R.T.). MerTK signaling induces functional inhibition of 
DC and blocks secretion of IL-12p70, up-regulation of co-stimulatory molecules and T cell 
stimulation. In vivo apoptotic β cells induce MerTK-dependent immunoregulation which 
prevents expansion and differentiation of type 1 CD4+ T cells. 
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Materials and methods 
Mice 
NOD/LtJ “NOD”, NOD.Cg-Tg(TcraBDC2.5)1Doi Tg(TcrbBDC2.5)2Doi “NOD.BDC2.5”, 
NOD-Tg(TcraCl4, TcrbCl4) “NOD.CL4” and BALB/c mice were maintained and bred under 
specific-pathogen free conditions. Establishment of MerTKKD mice has been described 
(Camenisch et al., 1999). Briefly, the tyrosine kinase domain of Mertk was replaced with a 
neomycin resistance gene, and B6.MerTKKD mice established. NOD MerTKKD mice were 
generated by breeding B6.MerTKKD and NOD mice, and then backcrossing the MertkKD gene 
onto the NOD genome for an additional 11 generations. At N11, Mouse MapPairs™ 
distinguishing B6, 129/Ola, and NOD/LtJ [Chr. 2 (D2Mit378, D2Mit94, D2Mit14, 
D2Mit393, D2Mit395, D2Mit190, D2Mit164, D2Mit256, D2Mit304, D2Mit224, D2Mit338, 
D2Mit307, D2Mit260, D2Mit309, D2Mit493, D2Mit451, D2Mit496, D2Mit287, D2Mit456, 
D2Mit265) (Invitrogen, Carlsbad, CA) were used in PCR according to the supplier’s 
directions to define a 17 cM segment derived from 129/Ola and containing MertkKD. Use of 
mice was approved by the Institutional Animal Care and Use Committee of the University of 
North Carolina at Chapel Hill. 
 
Preparation of BMDC and sDC 
    BMDC and sDC were prepared from male or female mice between 8-12 weeks as 
described (Bhattacharyya et al., 2004).  
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Flow cytometry  
    The following monoclonal Abs used for fluorescence staining were purchased from BD 
PharMingen (San Diego, CA): FITC-anti-CD40, FITC-anti-CD86, FITC-anti-CD80, PE-anti-
CD11c, APC-anti-CD11c and PE-anti-IFNγ. Goat polyclonal affinity purified anti-MerTK, 
anti-Gas6 and normal goat IgG were purchased from R&D Systems (Minneapolis, MN). 
Biotinylated anti-goat IgG was obtained from Vector Laboratories (Burlingame, CA). anti-
CD16/32 for Fc blocking, PerCP-streptavidin and PE-streptavidin were purchased from BD 
Pharmingen. Stained cells were analyzed on a FACScan or FACScalibur (BD Biosciences, 
San Jose, CA) using Summit Software (Cytomation, Ft. Collins, CO). 
 
Pretreatment of DC with apoptotic cells 
    Thymocytes prepared from 4-6 week old mice, were adhered to plastic for 2 hr to remove 
DC and macrophages, irradiated at 600 rad and then cultured in base medium for 12 hr.  
Flow cytometry demonstrated >95% apoptotic and <1% necrotic thymocytes based on 
Annexin-V and propidium iodide staining. Apoptosis was confirmed via DNA fragmentation 
analysis. DC were co-cultured with apoptotic cells at a ratio of 1:10 (DC:apoptotic cell) for 
3hr. In some experiments, DC were treated with anti-MerTK Ab prior to apoptotic cell 
incubation. Briefly, DC (5x106/well) were incubated with anti-mouse FcγIII/II (BD 
PharMingen) in 6-well ultra-low cluster plates for 0.5 hr at 37oC to block Fc receptor 
binding. DC were then treated for 1 hr at 37oC with 20 µg of either goat anti-MerTK Ab 
(AF591, R&D Systems, Inc., Minneapolis, MN) or goat IgG (R&D Systems), an isotype 
control. Alternatively, some apoptotic cell samples were pretreated with polyclonal anti-Gas6 
or goat IgG (R&D) for 30 min. prior to co-culture with DC. 
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Phagocytosis of apoptotic cells 
    DC were tested for phagocytosis of apoptotic cells. Apoptotic thymocytes were stained 
with 2.5 µM Cell Tracker Green (Molecular Probes, Eugene, OR) and co-cultured with DC at 
a ratio of 5:1 for 6 hr at 37oC or 4oC. Cells were then cultured for 10 min in PBS with 2 mM 
EDTA and washed vigorously to remove non-ingested but bound apoptotic cells which was 
confirmed by confocal microscopy. DC were stained with APC-anti-CD11c and analyzed for 
ingestion of fluorescent apoptotic cells by flow cytometry. 
 
Measurement of IL-12 production from DC  
    DC (9x105/well) were pretreated with or without apoptotic cells for 3 hr, washed and then 
stimulated with LPS for 72 hr. Supernatants were collected and assayed for IL-12p70 in 
triplicate using an ELISA kit (BD PharMingen) following the manufacturer’s instructions. 
Intracellular IL-12 staining was performed by using the Cytofix/Cytoperm cell 
permeabilization kit (BD Biosciences, San Diego, CA) and PE-labeled anti-mouse IL-
12p40/70. Alternatively, DC were stimulated by crosslinking CD40. DC were cultured for 30 
min with 10µg/ml anti-CD40 IgM (HM40-3, BD Pharmingen). Crosslinking was induced by 
addition of anti-IgM antibody (G188-2, BD Pharmingen).  
 
DC:T cell stimulation assay  
    DC were pretreated (or not) with apoptotic cells for 3 hr, washed and plated in 24-well 
ultra-low cluster plates at 3x104 DC/well. BDC2.5 CD4+ or CL4 CD8+ T cells  (3x105/well) 
plus varying concentrations (0.1-100 µg/ml) of the I-Ag7-restricted BDC2.5 mimotope 
(RTRPLWVRME) or H2Kd-restricted influenza virus hemagglutinin peptide (IYSTVASSL) 
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were added, and cultures incubated for 72 hr. Supernatants were harvested and IL-2 
concentration measured in triplicate by a sandwich ELISA using the JES6-1A12 
(eBioscience, San Diego, CA), and biotinylated-JES6-EH4 anti-IL-2 Abs, and streptavidin-
HRP (BD PharMingen). Concentration of IL-2 was determined using a standard curve. 
    Splenic BDC2.5 CD4+ and CL4 CD8+ T cells were prepared by depleting DC, Mφ and B 
cells via magnetic cell sorting using anti-CD11c, anti-CD11b and anti-CD19 Ab-magnetic 
microbeads (Miltenyi Biotec, Auburn, CA), respectively. BDC2.5 CD4+ and CL4 CD8+ T 
cells were then positively selected using anti-CD4 or anti-CD8 Ab-magnetic microbeads 
(Miltenyi Biotec). Purity of BDC2.5 CD4+ and CL4 CD8+ T cells was routinely >98%. 
 
Streptozotocin treatment 
    Four week old NOD or NOD.MerTKKD mice were treated with either 120 mg/kg STZ 
(Sigma) or citrate saline buffer alone. Four hours later 5x106 NOD.BDC2.5 CD4+ CFSE-
labeled T cells were injected intravenously. Five days later, pancreatic lymph nodes and 
pancreatic islets were harvested, dissociated and stained for FACS analysis of T cell 
proliferation and IFNγ production. 
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Table 2.1 
 
Analysis of type 1 CD4+ T cell expansion in 
STZ-treated mice 
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Figure 2.1 
 
 
 
 
 
MerTK deficient DC are not immunoregulated by apoptotic cells when stimulated with 
LPS or CD40 ligation. (A) BMDC from NOD or NOD.MerTKKD/KD mice were untreated or 
co-cultured with apoptotic cells (AC) followed by stimulation with titrated doses of LPS for 
72hr. IL-12p70 production was determined by ELISA. (B) Ex vivo derived sDC from NOD 
and NOD.MerTKKD/KD mice were untreated or co-cultured with AC the treated with 1µg/ml 
LPS for 72hr and IL-12p70 levels were measured. (C) Ex vivo NOD sDC were untreated or 
co-cultured with AC. After 24hr culture with 1µg/ml LPS, sDC were stained for surface 
 57
markers and intracellular IL-12. (D) NOD (open histograms) and NOD.MerTKKD/KD (shaded 
histograms) BMDC were untreated or co-cultured with AC followed by stimulation with 100 
ng/ml LPS for 24hr. DC were stained for co-stimulatory molecules and gated on CD11c+ 
cells for analysis. (E) NOD and NOD.MerTKKD/KD BMDC were untreated or co-cultured 
with AC and the stimulated by crosslinking CD40. Production of IL-12p70 was measured, 
and (F) expression of CD40 was assessed by FACS as determined by mean fluorescence 
intensity (MFI). Student’s t test *p<0.001, †p=0.011 
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Figure 2.2 
 
 
 
 
MerTK is expressed by conventional DC. FACS analysis was performed to determine 
expression levels of MerTK on (A) BMDC, (B) CD11c+CD11b+ DC, (C) CD11c+CD8α+ DC 
and (D) CD11c+B220+ plasmacytoid DC. Shaded histograms represent background staining 
of NOD.MerTKKD/KD DC and open histograms represent MerTK staining on NOD DC. 
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Figure 2.3 
 
 
 
 
 
T cell stimulation by MerTK deficient DC is not inhibited by apoptotic cells. 
MerTKKD/KD BMDC were left untreated or co-cultured with apoptotic cells (AC). (A) DC 
were pulsed with BDC2.5 peptide and mixed with BDC2.5 CD4+ T cells and cultured for 
72hr. IL-2 was measured by ELISA. (B) DC or AC-treated DC were pulsed with HA peptide, 
cultured with CL4 CD8+ T cells for 72hr and IL-2 levels were determined. Student’s t test 
*p<0.001 
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Figure 2.4 
 
 
 
 
 
MerTK is phosphorylated upon apoptotic cell incubation. NOD BMDC were pre-blocked 
with either normal goat IgG isotype control Ab or goat polyclonal IgG anti-MerTK Ab for 
30min. Preblocked DC were left untreated or co-cultured with apoptotic cells (AC) for 10 or 
20 min at 37oC. Cell lysates were immunoprecipitated with anti-MerTK and Sepharose-
Protein G. Immunoprecipitated proteins were separated by SDS-PAGE, transferred to 
nitrocellulose membranes and immunoblotted with an anti-phosphotyrosine Ab (upper blot). 
Blots were stripped and re-probed with anti-MerTK Ab (lower blot).  
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Figure 2.5 
 
 
 
 
 
Blockade of MerTK prevents the inhibitory effects of apoptotic cells upon DC. (A-D) 
NOD BMDC were incubated with either isotype control Ab or anti-MerTK Ab prior to co-
culture with apoptotic cells (AC). (A) 72hr after stimulation with 100 ng/ml LPS, IL-12p70 
production was measured by ELISA. (B) Expression of co-stimulatory molecules was 
determined after 24hr of 100 ng/ml LPS treatment. Stimulation of (C) BDC2.5 CD4+ and (D) 
CL4 CD8+ for 72hr was determined by IL-2 ELISA. Student’s t test *p<0.001 
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Figure 2.6 
 
 
 
 
Blockade of MerTK prevents the inhibitory effects of apoptotic cells upon DC in 
BALB/c mice. (A-C) BALB/c BMDC were incubated with either isotype control Ab or anti-
MerTK Ab prior to co-culture with apoptotic cells (AC). (A) Expression of co-stimulatory 
molecules was determined 24hr after treatment with 100 ng/ml LPS. (B) 72hr after 
stimulation with 100 ng/ml LPS, IL-12p70 production was measured by ELISA. (C) 
Stimulation of CL4 CD8+ was determined by IL-2 ELISA. Student’s t test *p<0.001 
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Figure 2.7 
 
 
 
 
 
 
Gas6 expression on the surface of apoptotic cells is essential for the inhibitory effects 
upon DC. (A) FITC-VAD-FMK negative (non-apoptotic) thymocytes (shaded histograms) 
and FITC-VAD-FMK positive (apoptotic) thymocytes (open-histograms) were stained with 
isotype control Ab (upper panels) or anti-Gas6 Ab (lower panels). (B) Thymocyte lysates 
were prepared from fresh untreated (U/T) thymocytes or at various time points after 
induction of apoptosis by exposure to 600 rad of gamma irradiation. Western blot for Gas6 
protein was performed (upper panel). 10ng of recombinant Gas6 protein was loaded as a 
positive control. (C) Gas6 was blocked by pre-incubation of apoptotic cells (AC) with 
polyclonal anti-Gas6 Ab. The effects of Gas6 blockade upon the inhibitory properties of AC 
on DC was determined by analysis of LPS-induced IL-12p70 production. 
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Figure 2.8 
 
 
 
 
MerTK deficient mice expressing a diabetogenic TCR transgene exhibit exacerbated 
T1D. NOD.BDC2.5 (n=10) and NOD.MerTKKD/KD.BDC2.5 (n=11) mice were monitored for 
diabetes based on urine glucose measurement for 52 weeks. Upon two consecutive readings 
above 250 mg/dL, mice were considered diabetic. Kaplan-Meyer log rank comparison 
p=0.013.  
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Figure 2.9 
 
 
 
 
Apoptotic β cell express Gas6 on their surface. Four week old NOD mice were injected 
i.p. with 120 mg/kg STZ. After 8hr, islets were purified and dissociated. Apoptosis was 
determined by staining with VAD-FMK-FITC. (A) Anti-Gas6 staining on non-apoptotic 
(shaded histogram) and apoptotic (open histogram) β cells. (B) Anti-Gas6 staining (open 
histogram) or isotype control staining (shaded histogram) of apoptotic β cells. 
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Figure 2.10 
 
 
 
 
MerTK deficiency causes enhanced T cell proliferation in vivo. NOD or 
NOD.MerTKKD/KD mice were treated with citrate saline control (Cit Sal) or 120 mg/kg STZ. 
2.5x106 CFSE-labeled BDC2.5 CD4+ T cells were adoptively transferred to each mouse. 72 
hr later pancreatic lymph nodes were harvested, dissociated and BDC2.5 CD4+ T cell 
proliferation was determined by FACS analysis. Numbers represent the percentage of total 
CFSE+ cells within each gate. Each descending peak in CFSE intensity represents one cell 
division.  
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Figure 2.11 
 
 
 
 
MerTK expression is not essential for phagocytosis of apoptotic cells by DC. (A and C) 
NOD BMDC or (B and D) NOD.MerTKKD/KD BMDC were co-cultured with Cell Tracker 
Green (CTG)-labeled apoptotic thymocytes for 6hr at 4oC or 37oC. Phagocytosis was 
measured by FACS analysis for the presence of CD11c+ CTG+ DC. 
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CHAPTER III 
MERTK-DEFICIENT NOD MICE ARE PROTECTED FROM DIABETES 
THROUGH ENHANCED THYMIC NEGATIVE SELECTION 
Mark A. Wallet, Pradip Sen, Carmen Wong, Yaming Wang, Clayton E. Mathews and Roland 
Tisch 
 
Abstract 
     Nonobese diabetic (NOD) mice exhibit several defects in the induction and/or 
maintenance of immune self-tolerance. As a result, autoreactive T cells mediate destruction 
of the insulin-producing β cells within pancreatic islets and type 1 diabetes (T1D) develops. 
Dendritic cells (DC) play critical roles in the induction of immune responses to foreign 
pathogens and tolerance to self antigens. Defects in immune regulation of DC may lead to a 
breakdown of self-tolerance and contribute to autoimmunity. The receptor tyrosine kinase 
Mer (MerTK) regulates DC activation/maturation. Here we show that MerTK-deficient NOD 
mice (NOD.MerTKKD/KD) are protected from autoimmune diabetes. Mononuclear cell 
infiltration of pancreatic islets (insulitis) is less severe in NOD.MerTKKD/KD mice. 
Additionally, the frequency of IFNγ-producing, β cell-specific CD4+ and CD8+ T cells within 
the islets of NOD.MerTKKD/KD mice is reduced relative to NOD mice which express MerTK. 
Notably, protection from T1D is due to enhanced thymic negative selection in MerTK-
deficient NOD mice, which results in depletion of autoreactive CD4+ and CD8+ T cell 
precursors.
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Introduction 
    The nonobese diabetic (NOD) mouse model of type 1 diabetes (T1D) closely parallels 
human T1D inheritance and pathology (Tisch and McDevitt, 1996). Several genetic 
susceptibility loci are shared between NOD mice and humans and similar β cell-specific 
antigens are targeted (Lieberman and DiLorenzo, 2003; Wicker et al., 1995). In NOD mice, 
progressive autoimmune-mediated destruction of pancreatic β cells occurs between 3 and 30 
weeks of age. Complete β cell destruction requires cooperation of several immune cell types 
including macrophages, dendritic cells (DC), B cells, CD4 and CD8+ T cells (Jansen et al., 
1994; Shoda et al., 2005; Wong and Janeway, 1999). Of particular importance are IL-12-
producing DC and type 1 CD4+ and CD8+ T cells (Anderson and Bluestone, 2005; Delovitch 
and Singh, 1997; Rabinovitch, 1994; Toyoda and Formby, 1998). 
    Comparisons between NOD and non-diabetic, congenic strains such as NOR have helped 
to identify critical checkpoints in the autoimmune process (Andre et al., 1996). The first 
checkpoint, occurring at approximately 3 weeks of age, (Checkpoint 1) involves the initial 
pathology of T1D marked by a peripheral mononuclear cell infiltrate of the islets (peri-
insulitis) (Bergman and Haskins, 1994; Kaufman et al., 1993). From 3 weeks to about 12 
weeks of age, insulitis progresses and invades the islet structure (intra-insulitis). Despite the 
presence of islet infiltrating CD4+ and CD8+ T cells during this phase, the majority of β cell 
mass remains intact (Andre et al., 1996). At approximately 12 weeks of age, however, a shift 
toward more “aggressive” insulitis occurs resulting in massive β cell destruction and overt 
diabetes. T1D development following Checkpoint 2 requires expansion of type 1 CD4+ and 
CD8+ T cells within the islets (Andre et al., 1996; Liblau et al., 1995; Rabinovitch, 1994; 
Rothe et al., 2001)  
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    The NOD mouse is characterized by several defects in peripheral and central tolerance. 
NOD mice demonstrate defects in regulatory NKT cells (Cardell, 2006), a general skewing 
towards type 1 T cell effectors (Raz et al., 2005) and aberrant development and function of 
natural immunoregulatory CD4+ CD25+ T cells (Treg) (Pop et al., 2005; Wu et al., 2002). In 
addition to peripheral immune defects, alterations in thymic selection contribute to survival 
and thymic emigration of high-avidity β cell-specific CD4+ and CD8+ T cells. The events 
contributing to inefficient negative selection in NOD mice are poorly understood, however, 
the diabetogenic I-Ag7 major histocompatibility complex (MHC) class II allele likely plays a 
role. Inefficient binding of self-peptides by I-Ag7 expressed by medullary thymic epithelial 
cells is believed to lead to an increased frequency of β cell-specific T cell precursors in NOD 
mice. (Rosmalen et al., 2002). Furthermore, defects in T cell signaling promote survival of 
low-avidity CD4+ CD8+ double-positive (DP) thymocytes which would typically die by 
neglect further enhancing the development of pathogenic β cell-specific CD8+ T cells (Kwon 
et al., 2005). 
    T1D in humans and NOD mice is controlled by many genetic loci and poorly understood 
environmental factors. Studies have identified as many as 25 T1D susceptibility or resistance 
loci (Idd1 to Idd25) in NOD mice (Barker, 2006; Kim and Polychronakos, 2005; Wicker et 
al., 1995). Approximately 50% of T1D inheritance is encoded by the Idd1 locus which 
encodes I-Ag7 MHC class II as well as MHC class I molecules H2Kd  and H2Db. (Tisch and 
McDevitt, 1996; Wicker et al., 1995). A host of non-MHC genes also contribute to T1D 
susceptibility. The Idd13 locus, located on murine chromosome 2 (syntenic on human 
chromosome 2) contributes to T1D susceptibility via at least two genes. The first encodes the 
MHC class I-associated protein β2-microglobulin (β2m) (Serreze et al., 1998). A diabetes-
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permissive b2m-a allele is carried by NOD and other strains. On the other hand, C57BL/6 
mice carry a diabetes-resistant b2m-b allele which, when introgressed onto the NOD genetic 
background, reduced the frequency of diabetes (Serreze et al., 1998). In addition to b2m, a 
second unidentified gene within Idd13 confers additional susceptibility to T1D. Evidence 
suggests that the il1 gene cluster, located in Idd13 once a likely candidate gene, has only a 
marginal impact on T1D development (Thomas et al., 2004). The mertk gene is also located 
within Idd13. Currently, no evidence suggests that mertk is involved in T1D inheritance, but 
we have identified at least three different mertk alleles in mice (Table 3.1).  
    The MerTK tyrosine kinase receptor and related family members Axl and Tyro3 contribute 
to peripheral immune regulation in mice (Lu and Lemke, 2001). MerTK is a 984 amino acid 
transmembrane protein with distinct extracellular ligand-binding domains and intracellular 
tyrosine kinase domain (Figure 1.3). MerTK deficient mice were created by targeted deletion 
of the tyrosine kinase domain resulting in a MerTK “kinase-dead” (MerTKKD) molecule 
(Camenisch et al., 1999) that is no longer expressed. MerTK deficiency results in impaired 
phagocytosis of apoptotic cells by macrophages and retinal pigment epithelial (RPE) cells 
(Cohen et al., 2002; Feng et al., 2002; Scott et al., 2001). Additionally, lack of MerTK, Axl 
and Tyro3 expression results in profound immune dysregulation and lymphoproliferative 
disease (Lu and Lemke, 2001). Based on these findings, it has been proposed that this family 
of receptor tyrosine kinases plays a key role in regulation of peripheral immune homeostasis. 
    MerTK mediates the inhibitory effects of apoptotic cells on DC via the phosphatidylserine 
opsonin Gas6 (Chapter 2). In the periphery, AC-induced inhibition of DC activation likely 
contributes to self-tolerance. For example, C57BL/6 mice lacking MerTK expression develop 
systemic lupus-like autoimmunity (Cohen et al., 2002). Furthermore, lack of MerTK 
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expression leads to exacerbated T1D development in NOD mice expressing the diabetogenic 
BDC2.5 TCR transgene (Chapter 2) supporting the idea that MerTK is essential for 
peripheral immune regulation. 
    Data is presented here supporting a novel role for MerTK in regulation of thymic 
selection. NOD mice lacking MerTK expression (NOD.MerTKKD/KD) demonstrate enhanced 
deletion of autoreactive T cell precursors within the thymus and protection from T1D. We 
propose that thymic DC hyper-activation in NOD.MerTKKD/KD thymi compensates for 
defects in negative selection of NOD mice. 
 
 
Results 
NOD.MerTKKD/KD mice are protected from diabetes 
    Female NOD mice develop overt diabetes beginning at approximately 12 weeks of age and 
by 30 weeks, approximately 80% of female mice are diabetic (Kikutani and Makino, 1992; 
Wicker et al., 1995). The NOD.MerTKKD/KD line of mice used in this study contained a 17 
cM segment of 129/Ola chromosome 2 harboring the MerTKKD mutation that was 
introgressed 11 backcross generations (see Materials and Methods). Female 
NOD.MerTKKD/KD, heterozygous NOD.MerTK+/KD mice and wildtype littermates were 
followed 52 weeks for diabetes incidence. No significant difference in the onset or frequency 
of diabetes was detected between NOD.MerTK+/+ (20/24) and NOD.MerTK+/KD (35/39) mice 
(Figure 3.1). In contrast, none of the NOD.MerTKKD/KD mice (0/30) developed diabetes 
(Figure 3.1). 
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    Analysis of insulitis revealed further differences between the respective groups of mice. 
NOD.MerTK+/KD pancreata had moderate insulitis at 12 weeks of age with approximately 
50% of islets showing no signs of insulitis (Figure 3.2A). Noteworthy is that the frequency 
and severity of insulitis in 12 week-old NOD.MerTKKD/KD mice was similar to that of 
NOD.MerTK+/KD mice (Figure 3.2A). By 17 weeks of age, islets prepared from 
NOD.MerTK+/KD mice were heavily infiltrated with only 20% remaining free of insulitis. On 
the other hand, 60% of islets from NOD.MerTKKD/KD mice remained free from insulitis 
(Figure 3.2A). 
    Next, the lymphoid composition of the islet infiltrates of the respective groups was 
examined. In 12 week-old NOD.MerTK+/KD mice, CD4+ T cells were dominant, consisting of 
58% of total lymphocytes within islet infiltrates, whereas CD8+ T cells and B cells made up 
26% and 16% respectively (Figure 3.2B). In contrast, B cells (47%) dominated the infiltrates 
of NOD.MerTKKD/KD mice and the frequency of CD4+ T cells (34%) and CD8+ T cells (19%) 
were markedly reduced (Figure 3.2B). Together, these results demonstrate that 
NOD.MerTKKD/KD mice remain diabetes-free and that this protection correlates with reduced 
insulitis and an altered composition of the islet infiltrate.  
 
 
NOD.MerTKKD/KD mice lack diabetogenic T cell effectors 
    IFNγ-producing CD4+ and CD8+ T cells, specific for β cell antigens, mediate destructive 
insulitis in NOD mice (Lieberman and DiLorenzo, 2003; Toyoda and Formby, 1998). CD4+ 
and CD8+ T cells from islet infiltrates of 12 week old NOD.MerTK+/KD and 
NOD.MerTKKD/KD mice were analyzed for reactivity to a panel of known β cell antigens and 
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mimetic peptides. An I-Ag7-restricted peptide corresponding to amino acids 9-23 of insulin B 
chain (InsB9-23) (Pankewycz et al., 1991) stimulated significantly more IFNγ-producing 
CD4+ T cells from NOD.MerTK+/KD versus NOD.MerTKKD/KD islets (p<10-3) (Figure 3.3). 
Similarly, the frequency of  type 1 effectors, responding to full-length GAD65 or the BDC2.5 
mimetic peptide, were reduced in NOD.MerTKKD/KD versus NOD.MerTK+/KD mice (Figure 
3.3). Compared to NOD.MerTKKD/KD islets, NOD.MerTK+/KD islets also had a greater 
frequency of IFNγ-producing H2Kd-restricted CD8+ T cells specific for a peptide epitope of 
islet-specific glucose-6-phosphatase associated protein (IGRP) (p=0.005), an IGRP mimetic 
peptide (NRPV7) (p<10-3) and a peptide corresponding to amino acids 15-23 of insulin B 
chain (InsB15-23) (p=0.042) (Figure 3.3). No IL-4- or IL-10-producing CD4+ or CD8+ T 
cells were detected in NOD.MerTK+/KD or NOD.MerTKKD/KD islets when stimulated with the 
panel of autoantigens (data not shown).  
    To further assess the frequency of β cell-specific CD8+ T cells within the islets, H2Kd 
tetramers, complexed with NRPV7 mimetic peptide were utilized. The frequency of NRPV7-
specific CD8+ T cells infiltrating the islets of NOD.MerTK+/KD mice (9.4%) was increased 
relative to NOD.MerTKKD/KD mice (2.3%) (Figure 3.4). Together, these data demonstrate that 
NOD.MerTKKD/KD mice have a significantly reduced frequency of β cell-specific type 1 
CD4+ and CD8+ T cells. 
 
 
Negative selection is enhanced in NOD.MerTKKD/KD mice 
    The reduced frequency of β cell-specific CD4+ and CD8+ T cells in NOD.MerTKKD/KD 
mice suggested that thymic selection was altered. Fetal thymic organ cultures (FTOC) were 
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prepared to examine thymic selection in vitro. Addition of BDC2.5 peptide to 
NOD.MerTK+/KD.BDC2.5 FTOC induced depletion of DP thymocytes and a concomitant 
increase in SP CD8+ thymocytes (Figure 3.5). Strikingly, depletion of DP thymocytes 
(p=0.003) and the increase in SP CD8+ thymocytes (p=0.015) were significantly enhanced in 
NOD.MerTKKD/KD.BDC2.5 FTOC (Figure 3.5).  
    To assess thymic selection in vivo, NOD.MerTK+/KD.BDC2.5 and 
NOD.MerTKKD/KD.BDC2.5 mice were injected i.v. with 400 µg of BDC2.5 mimetic peptide 
and apoptosis in DP thymocytes was measured 8 hours later. In NOD.MerTK/KD.BDC2.5 
mice, a 3.2-fold increase in apoptotic DP thymocytes was detected, relative to control 
ovalbumin (Ova) peptide-treated mice (Figure 3.6). In contrast, a 10-fold increase in 
apoptotic DP thymocytes was detected in BDC2.5 peptide-treated versus Ova peptide-treated 
NOD.MerTKKD/KD.BDC2.5 mice (Figure 3.6). The increased frequency of apoptotic DP cells 
in MerTK-deficient thymi was not due to inefficient phagocytosis of apoptotic cells, as 
induction of thymocyte apoptosis with dexamethasone indicated no difference in apoptotic 
cell clearance at the same 8 hour timepoint analyzed above (data not shown). These data 
demonstrate that NOD mice lacking MerTK expression have an increased capacity to delete 
autoreactive T cell precursors within the thymus. 
 
 
Bone marrow-derived precursors promote diabetes protection in NOD.MerTKKD/KD 
mice 
    Both medullary thymic epithelial cells and DC play roles in negative selection (Anderson 
et al., 2002; Liu, 2006; Wu and Shortman, 2005) and thus it was essential to determine which 
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population contributes to the phenotype observed in MerTK-deficient mice. Bone marrow 
chimera mice were established whereby NOD.MerTK+/KD or NOD.MerTKKD/KD irradiated 
recipient mice were reconstituted with bone marrow prepared from NOD mice transgenic for 
green fluorescent protein (GFP) (NOD.GFP). Reconstituted animals were characterized by 
GFP+ leukocyte populations as well as GFP+ thymic DC. Diabetes developed in both 
NOD.MerTK+/KD and NOD.MerTKKD/KD recipient groups a similar time of onset and 
frequency (Figure 3.7A). Additionally, irradiated NOD mice were reconstituted with 
NOD.MerTK+/KD.GFP or NOD.MerTKKD/KD.GFP bone marrow. Reconstitution was 
successful among peripheral leukocytes and thymic DC. Several recipients of 
NOD.MerTK+/KD.GFP bone marrow (5/9) developed diabetes by 16 weeks of age. 
Meanwhile, recipients of NOD.MerTKKD/KD.GFP bone marrow (8/8) remained diabetes-free 
for 16 weeks (Figure 3.7B). Analysis of this experimental group is ongoing, however, the 
delay in T1D progression in recipients of MerTK-deficient bone marrow is statistically 
significant (p=0.015). The effects of MerTK-deficiency upon protection from diabetes are 
clearly bone marrow-derived and thus it is likely that T1D prevention in NOD.MerTKKD/KD 
is mediated by thymic DC.  
 
 
MerTK-deficiency alone mediates protection from T1D 
    In view of the fact that the mertk gene is located within the Idd13 diabetes susceptibility 
locus, a concerted effort was made to determine whether the null allele was directly linked to 
the phenotype observed in NOD.MerTKKD/KD mice. Genetic mapping by microsatellite 
marker analysis showed that a 17cM region of parental 129/Ola genome flanked the mertk 
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gene in NOD.MerTKKD/KD mice (Figure 3.9). 129/Ola mice express the diabetogenic b2m-a 
allele, which was confirmed in NOD.MerTKKD/KD mice by restriction fragment length 
polymorphism analysis (data not shown). To determine the potential impact of other 
129/Ola-derived diabetes resistance genes within Idd13, a control congenic mouse was 
established. Specifically, the 129/Ola Idd13 gene region was introgressed onto the NOD 
genetic background for 5 generations using a speed congenic approach. Importantly, 
NOD129.Idd13 mice developed diabetes at a similar time of onset and frequency compared to 
NOD littermates (Figure 3.9). These results support our conclusion that MerTK-deficiency is 
directly involved in T1D protection in NOD.MerTKKD/KD mice. 
 
 
Discussion 
    NOD mice present with pathogenic autoreactive CD4+ and CD8+ T cells which mediate β 
cell destruction and T1D (Toyoda and Formby, 1998). Defects in both central (Brimnes et al., 
2002; Kwon et al., 2005; Moustakas et al., 2000; Naquet et al., 1999; Rosmalen et al., 2002; 
Savino et al., 1991; Stratmann et al., 2000; Thomas-Vaslin et al., 1997) and peripheral 
(Colucci et al., 1997; Pop et al., 2005; Wu et al., 2002) tolerance contribute to T1D 
pathogenesis. MerTK mediates immune regulation of DC function in the periphery and 
thymus which, in its absence, significantly impacts the autoimmune phenotype of NOD mice. 
    Lack of diabetes in NOD.MerTKKD/KD mice correlated with a reduced frequency of 
insulitis and type 1 CD4+ and CD8+ T cell effectors. Noteworthy is that the frequency of 
insulitis was equivalent among the respective groups of mice up 12 weeks of age. Beyond 
this age, however, the progression of insulitis was effectively blocked in NOD.MerTKKD/KD 
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mice. This is consistent with studies indicating that the transition from Checkpoint 1 to 
Checkpoint 2 involves TCR affinity/avidity maturation and expansion of type 1 T cell 
effectors (Andre et al., 1996; Hoglund et al., 1999; Lieberman and DiLorenzo, 2003). In 
NOD.MerTKKD/KD mice, this process is prevented at the level of precursor deletion in the 
thymus, thus effectively altering the lymphoid composition of the islet infiltrate and 
subsequent β cell destruction. 
     The previously-described role of MerTK in regulating the activational status of APC 
(Chapter 2) provides an alternative explanation for protection from diabetes in MerTK-
deficient NOD mice. Namely, macrophage and DC which typically express MerTK could be 
dysregulated in MerTK-deficient animals leading to defective expansion of pathogenic 
effector T cells. Extensive analysis of NOD.MerTK+/KD and NOD.MerTKKD/KD macrophage 
and DC functions was performed and no differences were observed in macrophage or DC 
function with regard to activation, maturation, cytokine production or T cell stimulation 
(Table 3.2) Furthermore, adoptive transfer of diabetogenic BDC2.5 CD4+ T cells induced 
diabetes at a similar rate in both NOD.MerTK+/KD and NOD.MerTKKD/KD recipients (data not 
shown). The only observed differences between NOD and NOD.MerTKKD/KD APC function 
were seen when DC were pretreated with apoptotic cells (Table 3.2), as described in Chapter 
2. These data indicate that peripheral APC function is sufficient to induce effector T cell 
differentiation and β cell destruction in the absence of MerTK expression. Additionally, 
NOD.MerTKKD/KD islets are not intrinsically resistant to immune-mediated destruction as 
adoptive transfer of BDC2.5 CD4+ T cells induces T1D efficiently. 
    NOD.BDC2.5 TCR transgenic mice develop a uniform population of CD4+ T cells which 
recognize an unknown β cell antigen (Stratmann et al., 2000). BDC2.5 T cells are not 
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negatively selected within the thymus as evidenced by unfettered emigration from the thymus 
(Dobbs and Haskins, 2001). Analysis of FTOC demonstrated that cognate TCR/MHC-
peptide interaction in BDC2.5 thymi induced negative selection and the efficiency of 
negative selection in NOD.MerTKKD.KD.BDC2.5 thymic lobes was significantly enhanced 
(Figure 3.5). This data was corroborated by in vivo analyses demonstrating similarly 
enhanced negative selection and induction of apoptosis in DP thymocytes in 
NOD.MerTKKD/KD.BDC2.5 mice (Figure 3.6) Negative selection is believed to be mediated 
by both medullary thymic epithelium and thymic DC (Anderson et al., 1998; Anderson et al., 
2002; Brocker, 1997; Matzinger and Guerder, 1989; Wu and Shortman, 2005). Importantly, 
protection from diabetes in MerTK-deficient mice was found to be associated with bone 
marrow-derived cells, strongly arguing that DC were promoting enhanced negative selection. 
(Figure 3.8).  
    MerTK has a direct role in regulation of DC activation/maturation (Chapter 2). 
Accordingly, thymic DC in MerTK-deficient mice may exhibit an enhanced activational 
status and thus, induce more efficient deletion of autoreactive T cell precursors. Changes in 
expression of MHC molecules, co-stimulatory molecules or cytokines may all contribute to 
alterations in thymic selection efficiency. As we have shown, apoptotic cells inhibit DC 
activation in vitro and in vivo (Chapter 2). With this in mind, we propose that the activational 
status of thymic DC is regulated by apoptotic thymocytes. In this way, thymic DC cannot 
obtain an enhanced state of activation and in turn promote “purging” of the TCR repertoire. 
In the absence of MerTK expression, thymic DC may obtain increased activational status that 
results in enhanced negative selection. Notably, preliminary results indicate that differences 
in thymic DC activation and maturation appear to be subtle but nevertheless sufficient to 
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effectively delete β cell-specific precursors. Studies have been initiated to better understand 
the specific role of thymic DC in negative selection and the impact of MerTK deficiency 
upon this process. 
    T1D inheritance in mice and humans is complex with numerous susceptibility and 
resistance loci scattered throughout the genomes (Kim and Polychronakos, 2005; Wicker et 
al., 1995). Among these loci is Idd13 which contains b2m and at least one additional T1D 
susceptibility gene (Serreze et al., 1998). The mertk gene is located within Idd13 and 
sequence analysis has identified 3 distinct mertk alleles (Table 3.1). Perhaps allelic variants 
of mertk encode different levels of protein or proteins which exhibit different functions. As 
evidenced by the important role of MerTK in immunoregulation of DC by apoptotic cells 
(Chapter 2) and maintenance of homeostatic regulation of thymic selection, alterations in 
MerTK’s function among allelic variants could influence autoimmunity and immunity to 
pathogens. It is unclear if mertk allelic variations contribute to T1D inheritance, however 
investigations are underway to assess this possibility. 
 
 
Materials and methods 
Mice 
    NOD/LtJ, NOD.BDC2.5, NOD.CL4, NOD.MerTK+/KD.BDC2.5, 
NOD.MerTKKD/KD.BDC2.5 and NOD.GFP mice were maintained and bred under specific-
pathogen free conditions. Establishment of MerTKKD mice has been described (Camenisch et 
al., 1999). Briefly, the tyrosine kinase domain of mertk was replaced with a neomycin 
resistance gene, and B6.MerTKKD mice established. NOD.MerTKKD/KD mice were generated 
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by breeding B6.MerTKKD and NOD mice, and then backcrossing the mertkKD gene onto the 
NOD genome for an additional 11 generations. At N11, Mouse MapPairs™ distinguishing 
B6, 129/Ola, and NOD/LtJ [Chr. 2 (D2Mit378, D2Mit94, D2Mit14, D2Mit393, D2Mit395, 
D2Mit190, D2Mit164, D2Mit256, D2Mit304, D2Mit224, D2Mit338, D2Mit307, D2Mit260, 
D2Mit309, D2Mit493, D2Mit451, D2Mit496, D2Mit287, D2Mit456, D2Mit265) 
(Invitrogen, Carlsbad, CA) were used in PCR according to the supplier’s directions to define 
a 17 cM segment derived from 129/Ola and containing MertkKD. Use of mice was approved 
by the Institutional Animal Care and Use Committee of the University of North Carolina at 
Chapel Hill. 
 
Islet Histology 
    Pancreata from NOD.MerTK+/KD and NOD.MerTKKD/KD mice were formalin fixed and 
embedded in paraffin for sectioning. 5µm sections were de-parafinized and stained with 
hematoxylin and eosin. Three sections, 100 µm apart, from each pancreas were analyzed. The 
total number of islets as well as islets demonstrating peri-insulitis and intra-insulitis were 
counted by light microscopy. 
 
Islet purification 
    Pancreata were perfused via the bile duct with collagenase P (Roche Diagnostics 
Corporation, Indianapolis, IN), dissociated and digested at 37oC. Islets were enriched by 
separation over a Ficoll gradient. Individual islets were picked with a siliconized Pasteur 
pipette under a dissecting microscope. Islets were dissociated in enzyme-free dissociation 
buffer (Gibco, Gran Island, NY). Where necessary, T cells were purified by magnetic bead 
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selection with microbeads coated with anti-CD3, anti-CD4 or anti-CD8 (Miltenyi Biotec, 
Auburn, CA).  
 
ELISPOT 
    Opaque 96-well immuspot plates were coated with 2 µg/ml purified anti-IFNγ antibody 
(BD Pharmingen, San Diego, CA). 5x106 irradiated splenocytes were added to each well as 
antigen presenting cells. 1x104 purified CD3+ lymphocytes from islets were added to each 
well. A panel of autoantigen peptides was added to individual wells at a concentration of 
10µg/ml. After 48hrs, IFNγ+ spots were identified by using 2 µg/ml biotinylated anti-IFNγ, 
streptavidin-HRP (BD Pharmingen) and 3-amino-9-ethyl carbazole substrate (Sigma-Aldrich, 
St. Louis, MO). Spots were counted using an Immuspot plate reader and software (Cellular 
Technology Ltd., Cleveland, OH).  
 
Tetramer staining 
    H2Kd MHC class I tetramers were prepared as described previously (Wong et al., 2006). 
Purified islets were cultured for 12 hrs in RPMI complete media with 2 ng/ml IL-2. Islets 
were dissociated and individual cells were stained with anti-CD3-FITC, anti-CD8-PerCP and 
PE-labeled tetramer loaded with either influenza nucleoprotein (NP) or NRPV7. Cells were 
analyzed by FACS using a BD FACSCalibur.  
 
FTOC 
    NOD.MerTK+/KD.BDC2.5 male and female mice were bred and timed pregnancies were 
established. On day 13 of gestation, pregnant females were sacrificed and fetuses were 
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removed. Fetal thymic lobes were individually removed under a dissecting microscope. Fetal 
liver samples were also taken for genotyping. Thymic lobes from individual mice were 
separated and placed on different Millicell culture plate insert discs (Millipore, Bedford, 
MA). Millicell discs were overlaid upon a small volume such that media contacted the 
membrane, however thymic lobes remained exposed to air. FTOC were allowed to grow for 
3 days without treatment. After 3 days, media was replaced with fresh media containing 
either 1µg/ml Ova peptide (ISQAVHAAHAEINEAGR) or 1µg/ml BDC2.5 peptide 
(RTRPLWVRME). Fresh media and peptide were replaced daily for 4 days. Thymic lobes 
were dissociated and stained for FACS with anti-CD3-FITC, anti-CD4-APC, anti-CD8-
PerCP and anti-Vβ4-PE (clonotypic TCR β chain encoded by BDC2.5 transgene).  
 
In vivo thymic selection 
    Four week-old female NOD.MerTK+/KD.BDC2.5 or NOD.MerTKKD/KD.BDC2.5 mice were 
treated with either 400 µg Ova or BDC2.5 peptide by i.v.  injection. Eight hours later mice 
were sacrificed and thymi were removed and dissociated. Thymocytes were stained with 
anti-CD4-APC, anti-CD8-PerCP, anti-Vβ4-PE and VAD-FMK-FITC and then analyzed by 
FACS. 
 
Bone marrow chimera mice 
    Bone marrow was isolated from tibias and femurs of NOD.GFP or NOD.MerTKKD/KD.GFP 
mice. CD4+ and CD8+ T cells were depleted with specific antibodies (GK1.5 and HO2.2 
respectively) and rabbit serum complement mediated lysis. 2x106 bone marrow cells were 
transferred intravenously to 4 week old NOD.MerTK+/KD or NOD.MerTKKD/KD mice that 
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received 950 rad of gamma irradiation. Chimerism was confirmed by GFP+ lymphocytes in 
peripheral blood samples. Chimeric mice were monitored for urine glucose for 30 weeks. 
Thymi were harvested and dissociated. Thymic DC were stained with anti-CD11c-APC and 
analyzed for GFP expression by FACS. 
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Table 3.1 
 
Allelic variants of mertk 
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Table 3.2 
 
Analysis of APC function in NOD.MerTK+/KD and NOD.MerTKKD/KD mice 
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 Figure 3.1 
 
 
 
 
MerTK-deficient NOD mice are protected from diabetes. Three groups of littermates 
were established after 11 generations of backcrosses to NOD. Animals were followed for 52 
weeks with weekly urine glucose monitoring. 
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Figure 3.2 
 
 
 
 
MerTK deficient NOD mice develop less severe insulitis. (A) 12 week old 
NOD.MerTK+/KD and NOD.MerTKKD/KD were sacrificed insulitis was scored by hematoxylin 
and eosin staining. (B) Islets were purified from 12 week old NOD.MerTK+/KD and 
NOD.MerTKKD/KD mice and lymphocytic infiltrates were characterized by FACS. 
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Figure 3.3 
 
 
 
MerTK-deficient NOD mice lack diabetogenic effector T cells in islet infiltrates. 
ELISPOT analysis of T cells from 12 week old NOD.MerTK+/KD and NOD.MerTKKD/KD 
mice was performed to determine the frequency of β cell-specific IFNγ+ T cells. Concavilin 
A (ConA) was use as a non-specific positive control. ConA results are plotted at 1/10 the 
recorded values for scale. (Student T test NRPV7 p<0.001, IGRP p=0.005, InsB9-23 
p<0.001, InsB15-23 p=0.042) 
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Figure 3.4 
 
 
 
 
The islets of NOD mice lacking MerTK expression have fewer β cell-specific CD8+ T 
cells. The frequency of CD8+ T cells expressing a diabetogenic NRPV7-specific TCR within 
the islets was determined by staining with NRPV7 tetramer and FACS analysis. Data are 
representative of 3 separate experiments which included 2-3 mice per group.  
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Figure 3.5 
 
 
 
 
Thymic negative selection is enhanced in MerTK-deficient NOD mice. Negative selection 
efficiency was determined by FACS analysis of FTOC. FTOC cultures were treated for 4 
days with either irrelevant Ova peptide or BDC2.5 peptide. Percentages are reflective of 3 
independent experiments. (Student’s T test *p=0.015, **p=0.003) 
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Figure 3.6 
 
 
 
 
Thymic selection is altered in vivo in MerTK-deficient NOD mice. 12 week old 
NOD.MerTK+/KD or NOD.MerTKKD/KD mice were intravenously injected with either 400µg 
Ova peptide or 400µg BDC2.5 peptide. Thymocyte apoptosis was determined by FACS 
analysis of VAD-FMK-FITC staining. 
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Figure 3.7 
 
 
 
 
Protection from diabetes in MerTK-deficient mice is a bone marrow-derived trait. (A) 
Bone marrow chimera mice were created by administration of NOD.GFP bone marrow to 
irradiated NOD.MerTK+/KD or NOD.MerTKKD/KD recipients. Animals were followed for 30 
weeks and urine glucose was measured weekly. (B) NOD mice were irradiated and 
reconstituted with either NOD.GFP bone marrow or NOD.MerTKKD/KD bone marrow. 
Diabetes was monitored weekly (Kaplan-Meyer log rank test p=0.015).  
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Figure 3.8 
 
 
 
 
The mertk gene is located within the diabetes susceptibility locus Idd13. Several Idd loci 
are distributed across many chromosomes of the mouse genome (Wicker et al., 1995).The 
MerTKKD mutation was introgressed for 11 generations to the NOD genetic background. A 
17cM segment of parental 129/Ola genomic DNA, including b2m and il1 remained flanking 
MerTK.  
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Figure 3.9 
 
 
 
 
Protection from diabetes is mediated by MerTK-deficiency and not by diabetes 
resistance alleles within 129/Ola Idd13. A congenic mouse which carries the Idd13 gene 
segment of 129/Ola on NOD background was analyzed for diabetes development. Urine 
glucose was monitored weekly. No significant difference was observed between NOD, 
congenic or heterozygous animals. 
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CHAPTER IV 
 
SUMMARY 
 
 
    The immune system must strike a constant balance between immunity and tolerance. 
The primary lymphoid tissues, bone marrow and the thymus, foster development of a 
diverse repertoire of B and T cells respectively. This diversity provides a broad spectrum 
of protection against a multitude of infectious pathogens including viruses, bacteria and 
eukaryotic parasites. In conjunction with development of “protective” B and T cells, the 
immune system must remove lymphocytes which would otherwise target self-antigens. 
Deletion of autoreactive B and T cells is the primary mechanism by which autoimmunity 
is prevented. T cell depletion occurs mainly within the thymus where medullary thymic 
epithelial cells and dendritic cells (DC) mediate negative selection. 
    Despite the efficiency of negative selection, deletion of all T cells, which may target 
countless self-antigens, is not possible. Thus, peripheral tolerance mechanisms provide 
and additional barrier against autoimmunity. For example, regulatory T cells (Treg) 
suppress the function of otherwise destructive, self-specific CD4+ and CD8+ T cells 
(Dejaco et al., 2006). Furthermore, peripheral DC prevent autoimmunity through various 
mechanisms (Wallet et al., 2005). One critical regulatory function of DC is recognition 
and phagocytosis of cells that die by apoptosis. Apoptotic cells induce functional changes 
in DC resulting in a “tolerized,” non-immunogenic phenotype. Thus, DC cannot induce 
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differentiation of pathogenic type 1 CD4+ and CD8+ T cells that target apoptotic cell-
derived self-antigens (Steinman et al., 2000; Stuart et al., 2002). 
    Failures in both central and peripheral tolerance contribute to development of T cell-
mediated autoimmune diseases such as type 1 diabetes (T1D). The findings discussed in 
Chapters 2 and 3 highlight the important roles of DC in peripheral and central tolerance 
respectively. Interestingly, a common defect, lack of MerTK expression, results in 
contrasting effects in the periphery versus the thymus. In the pancreatic lymph nodes 
(PLN), MerTK-deficient DC induce differentiation and expansion of pathogenic, β cell-
specific type 1 CD4+ T cells in response to β cell apoptosis. Within the thymus, however, 
MerTK-deficient DC mediate enhanced deletion of β cell-specific T cell precursors.  
    MerTK plays a role in immune tolerance as evidenced by mouse models of MerTK 
deficiency. Mice lacking MerTK expression (MerTKKD/KD) develop lupus-like 
autoimmunity with age (Camenisch et al., 1999; Cohen et al., 2002; Li et al., 2006). 
Furthermore, mice lacking MerTK expression, as well as related receptor tyrosine kinases 
Axl and Tyro3, develop severe autoimmunity and lymphoproliferative disorders (Lu and 
Lemke, 2001). The potential role for MerTK in DC was heretofore unknown, although 
previous works have implicated MerTK in phagocytosis of apoptotic cells by 
macrophages (Cohen et al., 2002; Scott et al., 2001; Wu et al., 2005) and retinal pigment 
epithelial cells (Hall et al., 2003; Hall et al., 2005; Hall et al., 2001; Wong and Janeway, 
1999). Thus, we have investigated the potential role of MerTK in immunoregulation of 
DC by apoptotic cells. 
    Non-obese diabetic (NOD) mice were utilized to assess the impact of MerTK-
deficiency in vitro and in vivo. DC from NOD.MerTKKD/KD mice were first used to 
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determine the role of MerTK in apoptotic cell-induced immunoregulation of DC (Chapter 
2). Findings are presented demonstrating that MerTK expression is essential to the 
inhibitory effects of apoptotic cells upon DC. Pretreatment of NOD, but not 
NOD.MerTKKD/KD DC prevented subsequent activation of the “tolerized” DC (Figure 
2.1) as well as stimulation of T cells by DC (Figure 2.3). 
    The effects observed in vitro predictably correlated with immune dysregulation in vivo. 
Induction of β cell apoptosis in NOD mice results in a “regulatory” DC phenotype within 
the PLN. As such, differentiation and expansion of β cell-specific type 1 CD4+ T cells 
within the PLN is inhibited (Hugues et al., 2002). In contrast, β cell apoptosis in 
NOD.MerTKKD/KD mice resulted in significant expansion of β cell-specific type 1 
effectors (Figure 2.10, Table 2.1). Furthermore, NOD.MerTKKD/KD mice expressing a 
diabetogenic β cell specific TCR transgene (NOD.MerTKKD/KD.BDC2.5) developed 
accelerated diabetes (Figure 2.8). We conclude that MerTK expression by DC is essential 
for maintenance of peripheral self-tolerance to apoptotic cell-derived antigens.  
    The findings from Chapter 2 may lead to the prediction that NOD.MerTKKD/KD mice 
would develop accelerated diabetes similar to NOD.MerTKKD/KD.BDC2.5 mice. In fact, 
we found that MerTK deficiency prevented spontaneous diabetes development in 
NOD.MerTKKD/KD mice (Figure 3.1). As shown in Chapter 3, NOD.MerTKKD/KD mice 
lack diabetogenic CD4+ and CD8+ T cells in the periphery (Figures 3.2-3.4. Consistent 
with the findings of Chapter 2, the deficit in β cell-specific typ1 1 T cells was not due to 
impaired expansion of effectors. Instead, we found that thymic negative selection was 
enhanced in NOD.MerTKKD/KD mice (Figures 3.5 and 3.6). This trait was conferred by 
bone marrow-derived antigen presenting cells (Figure 3.7), which we concluded were 
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thymic DC and not medullary thymic epithelial cells. It is likely that MerTK mediates 
regulation of thymic DC activation, thus allowing negative selection while preventing 
overzealous “purging” of the T cell repertoire.  
    Together, the findings of Chapters 2 and 3 support an essential role for MerTK in 
immune homeostasis. In the periphery MerTK mediates immunoregulation of DC by 
apoptotic cells. In the thymus, MerTK regulates DC activation and therefore negative 
selection efficiency. Interestingly, we found that in T cell-mediated autoimmunity, 
thymic selection can exhibit dominant tolerance. This is evident when comparing data 
from NOD.MerTKKD/KD mice with NOD.MerTKKD/KD.BDC2.5 mice. BDC2.5 CD4+ T 
cells are not deleted within the thymus, like due to lack of the cognate antigen. In 
NOD.MerTKKD/KD.BDC2.5 mice, immune dysregulation associated with MerTK-
deficiency was evident as diabetes was exacerbated. In contrast, NOD.MerTKKD/KD mice, 
in which the diverse T cell repertoire is subject to negative selection, are protected from 
diabetes due to MerTK-deficiency. This protection was dominant over the decidedly pro-
inflammatory peripheral environment in NOD.MerTKKD/KD mice. These findings 
highlight the important role of thymic selection in prevention of T cell-mediated 
autoimmunity. We will continue to investigate the specific role of DC in thymic negative 
selection and the phenotypic changes within NOD.MerTKKD/KD thymic DC which 
contribute to altered thymic selection. 
    It is interesting to note that mertk is located within the diabetes susceptibility locus 
Idd13 in mice and humans. As described in Chapter 3, we have identified three allelic 
variants of mertk among five mouse strains analyzed (Table 3.1). These alleles will be 
cloned and expressed in MerTKKD/KD DC to assess potential functional differences 
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between the molecules. Perhaps alterations in ligand-binding or signaling will result in 
differential DC function in the thymus or periphery. Such differences could impact 
susceptibility to type 1 diabetes or other autoimmune diseases. 
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Abstract 
    The paradigm of tolerogenic/immature versus inflammatory/mature dendritic cells (DC) 
has dominated the recent literature regarding the role of these antigen presenting cells (APC) 
in mediating immune homeostasis or self-tolerance and response to pathogens, respectively. 
This issue is further complicated by identification of distinct subtypes of DC which exhibit 
different APC effector functions. The discovery of pathogen-associated molecular patterns 
(PAMP) and Toll-like receptors (TLR) provide the mechanistic basis for DC recognition of 
specific pathogens and induction of appropriate innate and adaptive immune responses. Only 
recently has insight been gained into how DC contribute to establishing and/or maintaining 
immunological tolerance to self. Soluble and cellular mediators have been reported to 
effectively regulate the function of DC by inducing several outcomes ranging from non-
inflammatory DC which lack the ability to induce T lymphocyte activation, to DC which 
actively suppress T lymphocyte responses. A thorough discussion of these stimuli and their
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outcomes is essential to understanding the potential for modulating DC function in the 
treatment of inflammatory disease conditions. 
 
Introduction 
    DC have long been recognized as highly potent APC. Upon activation, DC process and 
present antigen and express high levels of co-stimulatory and major histocompatibility 
complex (MHC) molecules, in addition to secreting various cytokines and chemokines which 
initiate and/or enhance many T and B lymphocyte responses (Alaniz et al., 2004). These 
responses include: 1) induction of CD4+ T lymphocyte type 1 and type 2 subset 
differentiation (Alaniz et al., 2004; Eisenbarth et al., 2003; Maldonado-Lopez and Moser, 
2001), 2) CD8+ T lymphocyte activation and enhancement of cytotoxic T lymphocyte (CTL) 
activity (Smith et al., 2004), and 3) B lymphocyte maturation, Ig class-switching and 
antibody production (Gerloni et al., 1998; MacPherson et al., 1999). Only recently, however, 
has the tremendous versatility of DC become apparent. Beyond simple antigen capture, 
presentation and co-stimulation, DC play a unique role in tailoring immune responses to 
individual pathogens (de Jong et al., 2004; Proietto et al., 2004). Additionally, DC are 
important mediators of peripheral immune tolerance and maintenance of immune 
homeostasis (Gad et al., 2003). In the past, these contrasting roles of DC have been described 
primarily as a function of maturation. Immature DC largely being non-inflammatory or 
tolerogenic, whereas mature DC able to elicit a pro-inflammatory response. Although 
generally correct, this paradigm is now proving to be too simple.  
    DC arising from myeloid- or lymphoid-derived precursors exhibit an immature phenotype, 
characterized by a high phagocytic capacity and low expression levels of co-stimulatory 
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molecules such as CD40, CD80 and CD86 (Mahnke et al., 2002). The many phagocytic 
receptors of DC allow ingestion of a wide variety of antigens including microbial pathogens 
or necrotic tissue laden with microbial antigens. Adhesion to, and phagocytosis of microbes 
by DC is dependent on several receptors including CD14, scavenger receptor-A (SR-A) (van 
Oosten et al., 1998), and the Fc receptors (FcR) FcγR1, FcγR2b and FcγRIII (Regnault et al., 
1999; Schuurhuis et al., 2002; Tobar et al., 2004). These pathways of phagocytosis lead to 
antigen processing mechanisms that load microbial peptides typically onto MHC class II for 
presentation to CD4+ T lymphocytes. Notably, DC defined by expression of CD8α are also 
efficient in shuttling phagocytosed antigens into the MHC class I pathway and subsequent 
presentation to CD8+ T lymphocytes (Albert et al., 1998a; Albert et al., 1998b). Upon 
phagocytosis and subsequent activation, DC found residing in peripheral tissues traffick to 
the draining lymph nodes, undergo further maturation, and present to and stimulate T cells 
specific for the cognate peptide.  
    Several factors can enhance DC maturation and promote a pro-inflammatory phenotype. 
PAMP-containing molecules of bacteria, viruses and parasites, such as lipopolysacchride 
(LPS), peptidoglycan (PGN), CpG motifs, flagellin, and viral nucleic acids, induce TLR 
signaling (Werling and Jungi, 2003). TLR signaling in DC serves two purposes. First, bodies 
that are phagocytosed in the presence of TLR signaling enter a specific phagosome 
maturation pathway. This pathway results in enhanced degradation of the engulfed material 
and efficient presentation of antigens (Blander and Medzhitov, 2004). Secondly, DC subsets 
express unique repertoires of TLRs, allowing for specialized responses to each class of 
pathogen(Proietto et al., 2004). For example, plasmacytoid DC (pDC) uniquely express TLR-
9 and therefore can respond to CpG DNA (Coccia et al., 2004). However, pDC do not 
  113
express TLR-4 and therefore respond to LPS weakly. In pDC, TLR-9 ligation results in high 
production of type-I interferons (IFN-α and IFN-β) enhancing pDC survival and promoting 
increased MHC expression by neighboring APC. Throughout the DC family, engagement of 
the various TLRs results in production of several pro-inflammatory cytokines including type-
I interferons, TNF-α, IFN-γ, IL-12 and IL-1 (Proietto et al., 2004). These unique responses, 
tailored by each DC subset, serve to enhance innate immune responses at the site of 
inflammation, and guide adaptive immunity. The characteristics of murine DC subsets have 
been thoroughly reviewed by Wilson et al. (Wilson and O'Neill, 2003) and are summarized 
in Table 1. 
    The above pattern response mechanisms driving inflammation and adaptive immunity to 
pathogens have established a paradigm for recognition of non-self molecules. Overlooked 
until recently, however, is the role and in turn how DC prevent autoreactivity and/or tolerize 
existing autoreactive T cells. For the purpose of this review, we will focus on key soluble and 
cellular immunoregulators that effectively promote a “tolergenic” phenotype in DC.  
 
Immunoregulation of DC by IL-10  
    The local cytokine environment is a key contributor to the establishment of DC phenotype. 
IL-10, a major anti-inflammatory cytokine is produced predominantly by Th2 lymphocytes, 
Tr1 regulatory lymphocytes, and monocytes and macrophages (Moore et al., 2001). 
Treatment of immature DC with IL-10 in vitro induces an immunoregulatory phenotype that 
results in inhibition of CD4+ and CD8+ T lymphocyte reactivity in an antigen-specific 
manner (Steinbrink et al., 1999; Steinbrink et al., 1997; Yang and Lattime, 2003). Among 
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CD4+ T lymphocytes, both Th1 and Th2 responses can be inhibited by IL-10 treated DC 
(IL10DC) (Haase et al., 2002). Similarly, IL10DC mediate tolerance within CD8+ CTL.  
    IL-10 pretreatment effectively suppresses maturation of immature DC. Upon stimulation, 
IL10DC fail to: i) secrete pro-inflammatory cytokines including IL-6, IL-1β, TNF-α and IL-
12p70 (Driessler et al., 2004), and ii) up-regulate expression of co-stimulatory molecules 
such as CD40 and CD86 (McBride et al., 2002). Studies have demonstrated, however, that 
the tolergenic effect of IL10DC is not simply due to insufficient co-stimulation. Manavalan et 
al. reported that IL-10 treatment induced up-regulation of the inhibitory immunoglobulin-like 
transcript 3 (ILT3) and ILT4 (LIR-2) molecules on the surface of DC (Manavalan et al., 
2003). Importantly, IL10DC no longer induced T lymphocyte anergy upon treatment with 
blocking antibodies specific for ILT3 and ILT4. Furthermore, murine fibroblast L 
transfectants expressing ILT4 stimulated T lymphocyte proliferation, suggesting that the 
inhibitory effect of ILT4 is in fact DC-specific (Beinhauer et al., 2004). Evidence indicates 
that engagement of ILT4 by T lymphocytes promotes signaling within DC necessary for 
establishing an immunoregulatory phenotype. Interestingly, LPS stimulation of DC has also 
been found to elicit production of a soluble ILT4 molecule (sILT4) that enhances T 
lymphocyte activation. sILT4 may competitively block T lymphocyte binding of membrane 
bound ILT4 (mILT4) to favor a stimulatory DC phenotype. On the other hand, IL10DC upon 
LPS treatment fail to express sILT4 which would be expected to further promote the 
tolergenic capacity of IL10DC (Beinhauer et al., 2004). Interestingly, donor DC expressing 
ILT3 and ILT4 are associated with reduced rejection of murine heart transplants (Chang et 
al., 2002). The immunoregulatory properties of IL-10 upon DC are summarized in Figure 1. 
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    Although ineffective at mediating T lymphocyte activation, Nolan et al. demonstrated that 
IL10DC maintain the capacity to elicit innate immune responses to microbial pathogens 
(Nolan et al., 2004). Employing real-time PCR and SAGE, production of TLR-induced pro-
inflammatory molecules such as DCIP-1, MIP-2, CXCL-4, CXCL-5 and IL-1, in addition to 
proteins associated with phagocytosis were either unaffected or up-regulated in IL10DC 
treated with LPS. These factors typically enhance: i) recruitment and activation of 
neutrophils, and ii) phagocytosis of microbial debris, both of which are essential components 
of innate immunity. Consequently, IL10DC continue to mediate a pro-inflammatory response 
and clearance of pathogens. This work has helped to establish a paradigm whereby DC 
tolerance may not simply be a question of “on versus off” but rather “adaptive versus innate”. 
Future analysis of transcriptional regulation induced by IL-10 may shed light upon molecular 
switches that induce global changes in the ability of DC to mediate specific responses. 
    The signaling mechanisms responsible for phenotypic changes in DC following IL-10 
treatment remain largely unknown, but recent findings implicate phosphoinositol-3 kinase 
(PI3K)-and STAT3-dependent inhibition of NF-κB function (Bhattacharyya et al., 2004; 
Hoentjen et al., 2004). NF-κB is a key transcription factor that regulates various aspects of 
DC development, maturation and effector function. The IL-10 induced PI3K signaling 
pathway results in downstream blockade of NF-κB activation (Bhattacharyya et al., 2004). 
Additionally STAT3 activation, in response to IL-10, results in direct inhibition of NF-κB 
binding to the IL-12p40 promoter sequence (Hoentjen et al., 2004). Noteworthy is that the 
effects of IL-10 on signaling are distinct between macrophages and DC, and possibly 
between subsets of DC. Further research into the signaling mechanisms that control 
immunoregulatory DC differentiation are warranted. 
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    The many observations that IL-10 modulates DC effector function in a tolerogenic manner 
have spurred studies to assess the efficacy of using IL10DC to treat inflammatory disorders. 
Initial results have been promising and suggest that so-called DC “vaccines” may be useful in 
the treatment of various autoimmune diseases and rejection of allogeneic organ grafts. In 
addition, groups have engineered DC to express high levels of IL-10. In this way, the 
preferential trafficking of DC to sites of inflammation upon adoptive transfer, and the anti-
inflammatory properties of IL-10 can be exploited. For example, Coates et al. transduced 
human myeloid DC with an adenoviral recombinant encoding IL-10 gene (AdvIL-10) which 
upon transfer into a humanized NOD.scid mouse model, effectively protected human skin 
grafts (Coates et al., 2001).  
 
The role of TGF-β1 in regulating DC. 
    TGF-β1 belongs to a well defined multipotent cytokine family known to regulate several 
patho-physiological events. TGF-β, produced by T cells, monocytes/macrophages, and 
granulocytes is typically detected at sites of inflammation (Rastellini et al., 1995). Among the 
three isoforms of TGF-β, TGF-β1 exhibits the broadest spectrum of biological activities. 
Notably, TGF-β1 promotes early DC development in vitro, and suppression of immature DC 
activation and maturation (Ellingsworth et al., 1986; Yamaguchi et al., 1997). For example, 
TGF-β1 inhibits up-regulation of the costimulatory molecules CD83 and CD86 in humans 
(Strobl and Knapp, 1999) and CD80 and CD86 in mice (Zhang et al., 1999), thereby 
reducing the efficacy of DC to stimulate T lymphocytes.  
    One mechanism that contributes to the impaired stimulatory capacity of TGF-β1-treated 
DC may be the down-regulation of key immunomodulatory receptors. Mou et al. observed 
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that treatment of murine bone marrow-derived DC with TGF-β1 in vitro results in decreased 
expression of TLR-4. This finding correlated with reduced sensitivity to LPS-induced 
maturation of the DC(Mou et al., 2004). The inability to recognize pro-inflammatory 
microbial products as well as inhibitory signaling mechanisms likely combine to render TGF-
β1 DC ineffective in driving T cell immunity. 
    Additionally, TGF-β1 affects the trafficking of mature DC (Figure 2). For example, Ogata 
et al. have reported that TGF-β1 inhibits DC expression of the chemokine receptor CCR7. 
Consequently, TGF-β1 conditioned DC are unable to efficiently traffic to the draining lymph 
nodes in response to MIP-3β (Ogata et al., 1999). The molecular targets of TGF-β1 mediated 
suppression in DC remain ill defined. One such target, however, appears to be the 
transcription factor RunX3. For example, DC lacking expression of RunX3 are resistant to 
the immunoregulatory effects of TGF-β1(Fainaru et al., 2004).  
    Several strategies of immunotherapy have focused on the immunoregulatory properties of 
TGF-β1 upon DC maturation and effector function. Yarlin et al. employing TGF-β1-treated 
DC successfully suppressed experimental autoimmune myasthenia gravis (EAMG), an 
animal model of myasthenia gravis (MG) (Yarilin et al., 2002). Both EAMG and MG 
pathologies are the result of T cell-dependent antibody responses to the acetylcholine 
receptor (AChR). Adoptive transfer of splenic DC pretreated with TGF-β1 after Lewis rats 
were immunized with AChR protein, effectively suppressed ongoing EAMG characterized 
by reduced mortality and a diminished frequency of anti-AChR antibody producing cells. 
    Similarly, many groups have utilized TGF-β1-expressing adenoviral vectors (Adv-TGF) to 
modify DC function. These studies have consistently reported the ability of Adv-TGF-
transduced DC to inhibit syngeneic and allogeneic T cell responses. This inhibition includes 
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dominant suppression of allogeneic CD4+ and CD8+ effectors that have been primed by 
untreated DC (Asiedu et al., 2002). 
  
DC and immune homeostasis; the role of apoptotic cells. 
    DC activation is typically referred to in the context of a response to pathogens. 
Unperturbed environments foster maintenance of immature DC, while microbial pathogens 
induce differentiation to a specific mature/activated phenotype.  This representation of DC 
life cycle accurately represents a portion of immune regulation, but the model fails to address 
the activity of DC under homeostatic conditions. Multicellular organisms constantly harbor a 
mixed balance of viable, apoptotic and necrotic tissues. The continual exposure to self-
antigen necessitates that DC maturation and effector function to be regulated appropriately to 
maintain immunological tolerance. 
    The clearance of apoptotic cells in vivo is carried out by multiple phagocytes including 
macrophages, neutrophils and DC. In the case of DC, it is only immature cells that are 
capable of phagocytosing apoptotic cells. Binding and ingestion of apoptotic cells by 
immature DC is mediated by a group of receptors including phosphatidylserine receptor 
(PSR) (Li et al., 2003), CD36, αVβ5 integrin (Albert et al., 1998a), complement receptor 
C1qR and the receptor tyrosine kinase Mertk (Cohen et al., 2002).  
    In general, when DC encounter apoptotic cells, a non-inflammatory and tolerogenic 
phenotype typical of immature DC is observed (Steinman et al., 2000). For example, Stuart 
et. al. showed that DC pretreated with apoptotic cells exhibit a reduced capacity to produce 
IL-12p70 upon stimulation (Stuart et al., 2002). Interestingly, the effect was selective in that 
secretion of TNF-α was unaltered. Immature DC treated with apoptotic cells also exhibit an 
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impaired capacity to stimulate T lymphocytes. Notably, LPS treatment is unable overcome 
the “tolergenic” phenotype, indicating the effect of apoptotic cells is long-lasting and 
relatively stable (Takahashi and Kobayashi, 2003). As a result, activation of DC carrying the 
remnants of apoptotic cells is effectively prevented. In addition to maintaining an immature 
phenotype, apoptotic cells have been reported by Takahashi et al. to induce the expression of 
IL-6 and IL-12p40, and therefore further enhance the tolergenic function of the DC 
(Takahashi and Kobayashi, 2003). Apoptotic cell-induced IL-6 secretion by DC functions in 
an autocrine manner to block further maturation of DC. For example, activation of STAT3 
following IL-6 pretreatment blocks LPS-induced up-regulation of CD80, CD86, CD40 and 
MHCII, thereby reducing the T lymphocyte stimulatory capacity of the DC. Furthermore, IL-
6 has been reported to suppress TNFα- and PGN-mediated activation and maturation of DC. 
On the other hand, secretion of significant levels of IL-12p40 results in formation of IL-
12p40 homodimers, which competitively inhibit IL-12p70 binding to the IL-12 receptor on T 
lymphocytes (Trinchieri, 2003). Consequently, differentiation of naïve T lymphocytes into 
type 1 effectors is suppressed (Figure 3).  
    Sauter et al. have described how phagocytosis of apoptotic cells by DC affects cross-
presentation of self-antigens to CD8+ T lymphocytes (Sauter et al., 2000). Employing human 
DC and apoptotic versus necrotic 293 tumor cells, the importance of the mode of death of the 
phagocytosed cells was initially defined. Necrotic but not apoptotic 293 cells induced DC 
maturation based on up-regulation of CD83 and DC-LAMP. Furthermore, pulsing DC with 
necrotic allogeneic splenocytes resulted in a robust mixed lymphocyte reaction (MLR). In 
contrast, apoptotic allogeneic splenocytes failed to induce a significant MLR.  Furthermore, 
Furgeson et al.  demonstrated the potent effects of apoptotic cells on DC effector function in 
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vivo (Ferguson et al., 2002). Injection of apoptotic splenocytes coupled with trinitrophenol 
blocked in vitro recall responses to the hapten. Importantly, CD11c+CD8α+ DC were 
identified as the critical effectors for inducing the immune tolerance to apoptotic cell 
antigens.  
    These data and work by others support a role for DC in maintaining immunological 
homeostasis s(Basu et al., 2000; Stuart et al., 2002; Xu et al., 2004). In contrast, necrotic cells 
typical of microbial infections induce DC activation and maturation, and subsequent 
immunity. This balance in DC reactivity allows the peripheral immune system to continually 
monitor tissues for signs of death and mount the appropriate responses. The importance of 
DC in clearance of apoptotic cells and the maintenance of immune homeostasis is 
highlighted in autoimmune diseases such as systemic lupus erythemetosous (SLE). While not 
wholly causal for SLE, failure to effectively clear apoptotic cells contributes to the severity 
of disease (Gaipl et al., 2004). 
    We have recently undertaken studies to describe the signaling mechanisms responsible for 
apoptotic cell-induced DC tolerance. Initial results suggest that apoptotic cells block pro-
inflammatory stimuli, such as TLR and CD40 signaling through inhibition of NF-κB 
activation and nuclear translocation. Further analysis of the processes that mediate immune 
homeostasis by apoptotic cells will help define defects which contribute to autoimmunity, in 
addition to the development of rational modalities of immunotherapy for prevention and/or 
treatment of autoimmunity, and other pro-inflammatory diseases. 
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Signaling via CD80 and CD86 regulates DC activation/maturation. 
    T lymphocytes are frequently viewed as dependents of DC and other APC. Upon a cognate 
interaction, however, engagement by T lymphocytes of various cell surface molecules also 
induce signals which affect DC activation and/or maturation. For example, ligation of CD40 
by CD40L expressed on the surface of T lymphocytes delivers a potent activational signal for 
DC (Bennett et al., 1998; Hermans et al., 1999; Ridge et al., 1998; Schoenberger et al., 
1998). More recently, signals delivered by the co-stimulatory molecules CD80 and CD86 
have been shown to modulate DC activation and effector function (Zheng et al., 2004).  
Regulatory T lymphocytes (TReg) express the surface molecule CTLA-4 which binds CD80 
(and CD86) with high affinity(Munn et al., 2004). Following a cognate interaction between 
TReg and DC, CD80 signaling is induced which includes STAT-1 activation and subsequent 
secretion of IFN-γ (Logue and Sha, 2004). IFN-γ has an immediate autocrine effect upon DC 
resulting in the secretion of the enzyme indoleamine 2,3-dioxygenase (IDO) (Grohmann et 
al., 2002). IDO is an enzyme that catalyzes the breakdown of the amino acid tryptophan into 
N-formyl-kynurenine and various downstream metabolites. Importantly, depletion of 
tryptophan in the surrounding milieu has a profound effect upon T lymphocytes which can be 
reversed experimentally by substituting excess tryptophan (Munn et al., 1999; Munn et al., 
2002). T lymphocytes stimulated by peptide/MHC presented by IDO-producing DC undergo 
activation and then rapid cell death via apoptosis (Grohmann et al., 2001) (Figure 4).  
    As is the case for most mechanisms of immune deviation, CTLA-4 induced tolerance has 
an opposing force to deal with. In a fashion quite similar to the CTLA-4/CD80 signaling 
axis, activated T lymphocytes provide DC with a pro-inflammatory feedback stimulus. 
Expression of CD28 by activated T lymphocytes serves to ligate CD86 on DC(Orabona et al., 
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2004). This interaction induces a signaling cascade that results in p38 MAPK and NF-κB 
activation (Logue and Sha, 2004). Subsequently IFN-γ and IL-6 are produced. In this 
scenario, however, IFN-γ mediated induction of IDO is hampered by IL-6. IL-6 has been 
shown to dominantly block IFN-γ induced IDO expression and block the regulatory capacity 
of these DC (Grohmann et al., 2001). Indeed, expression of IL-6 by DC in this case drives a 
dominant pro-inflammatory response, as opposed to serving a suppressive role described 
above. This phenomenon further highlights the complexity of DC regulation and serves to 
warn against assignment of broad descriptive labels (i.e. regulatory) to cytokines. 
 
CD200R, a novel molecule regulating DC effector function. 
    A second model for IDO induction involves the widely expressed molecule CD200 (OX-2) 
and its receptor CD200R (Gorczynski et al., 2004). Ligation of CD200R on splenic pDC 
results in IDO secretion and antigen-specific immunoregulation, which in turn is mediated 
via induction of TReg (Fallarino et al., 2004). The mechanism by which IDO secreting pDC 
induce TReg has yet to be defined. The ubiquitous nature of CD200 expression by non-
immune cells suggests a role for CD200R-mediated tolerance in immune homeostasis. 
Furthermore, mice lacking CD200 expression demonstrate increased susceptibility to 
autoimmunity (Barclay et al., 2002; Nathan and Muller, 2001). Manipulation of 
CD200/CD200R signaling may prove to be a novel mechanism for induction of antigen 
specific immune tolerance. Such a system could be beneficial for clinical treatment of many 
inflammatory diseases such as type 1 diabetes, rheumatoid arthritis and multiple sclerosis.  
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Summary 
    Scientists have spent the better part of the past century attempting to manipulate the 
immune system. These efforts have primarily focused upon induction of immunity to 
pathogens. Currently, a major emphasis is the development of effective immunotherapies for 
the prevention and/or suppression of pro-inflammatory responses associated with 
autoimmunity and transplantation. In view of their central role in eliciting and regulating 
immunity, the application of DC for the purpose of immunotherapy is highly appealing.  
    Initial studies using IL-10- or TGF-β1-treated DC to induce antigen-specific immune 
tolerance have shown promise. As we gain further mechanistic insight into events regulating 
DC maturation and effector function, the therapeutic efficacy of DC-based “vaccines” will be 
enhanced. Techniques that allow for harvest, ex vivo culture and re-infusion of autologous 
DC have already been developed. Together with advances in gene therapy, the use of DC-
based vaccines will allow clinicians to manipulate the immune system in a safe and effective 
manner. 
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Table 1 
 
Multiple subsets of murine splenic dendritic cells perform specialized functions. 
 
DC subset  Markers   Function   
Myeloid   CD11c+CD205-CD11b+ Located in splenic marginal zones. 
    CD8α-CD4+/-  Efficient stimulation of CD4+ and CD8+   
       T cells. Favor Th2 differentiation during  
       inflammatory conditions 
 
 
Lymphoid  CD11c+CD205+CD11b- Efficiently cross-present exogneous 
    CD8α+CD4-  antigens to CD8+ CTL. Favor Th1  
       differentiation during inflammatory 
      conditions. Maintain cross-tolerance 
      to self antigens. 
 
Plasmacytoid  CD11c+CD11b-B220+ Possibly contribute to peripheral 
    GR1+/-   self-tolerance. Mediate anti-viral 
       responses through production of  
       IFN-α. 
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Figure 1 
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IL-10 induces immunoregulation of DC maturation. (A) LPS promotes T cell activation. 
When immature DC encounter inflammatory stimuli such as LPS, maturation ensues. NF-κB 
is activated, translocated to the nucleus and transcription of multiple genes is induced. Co-
stimulatory molecules CD80 and CD86, inflammatory cytokines (IL-6, IL-1β, TNF-α and IL-
12p70) and soluble ILT4 (sILT4, sLIR2) are produced, which supports activation of T cells. 
(B) IL-10 blocks the effects of LPS upon DC. IL-10 produced by monocytes, TH2 cells and 
Tr1 cells induces PI3K and STAT3 activation by DC. PI3K activation results in blockade of 
NF-κB activation and STAT3 blocks binding of NF-κB to the IL-12p40 promoter. 
Consequently, differentiation of Th1 T lymphocytes is inhibited. Additionally, IL-10 inhibits 
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production of sILT4, favoring instead expression of mILT4. Ligation of DC mILT4 by T 
lymphocytes induces a regulatory DC phenotype that induces Tr1 differentiation. 
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Figure 2 
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TGF-β1 modulated DC phenotype and T lymphocyte activation. TGF-β1 is produced by 
monocyte/macrophages, T lymphocytes or granulocytes or provided exogenously as a means 
of immunotherapy. DC which encounter TGF-β1 down regulate expression of CD80, CD86, 
TLR4 and importantly CCR7. Low expression of CCR7 inhibits MIP-3β-induced migration 
to lymph nodes. Therefore, T lymphocyte stimulation is inhibited. 
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Figure 3 
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Apoptotic cells induce immunoregulation and tolerance induction through DC. DC 
scavenge tissues for microbes and dying tissue. Apoptotic cells induce PI3K dependent 
signaling resulting in inhibition of NF-κB translocation and co-stimulatory molecule 
(CD80/86) expression. Production of IL-6, TGF-β and IL-12p40 ensue. IL-12p40 homdimers 
inhibit the effects of IL-12p70 upon T lymphocytes, effectively inhibiting Th1 induction. 
Apoptotic cells induce a lasting inhibitory effect which renders DC refractory to LPS induced 
stimulation of Th1 lymphocytes. 
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Figure 4 
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CTLA-4 and CD28 induce divergent outcomes in DC maturation. TReg cells expressing 
CTLA-4 ligate CD80 on DC inducing STAT-1 activation, IFN-γ production and IDO 
production. IDO catalyzes the breakdown of tryptophan which results in T lymphocyte 
activation followed by rapid induction of apoptosis. In contrast, activated T lymphocytes 
expressing CD28 induce activational signals through CD80/CD86. Receptor ligation induces 
p38 MAPK and NF-κB activation. IL-6 and IFN-γ are then produced. IL-6 induces a 
dominant antagonistic effect upon IDO production. DC are now capable of inducing T 
lymphocyte activation and proliferation. 
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Abstract 
    Dendritic cells (DC) play a key role in immune homeostasis and maintenance of self-
tolerance. Tolerogenic DC can be established by an encounter with apoptotic cells (AC) and 
subsequent inhibition of maturation and effector functions. The receptor(s) and signaling 
pathway(s) involved in AC-induced inhibition of DC have yet to be defined. We demonstrate 
that pretreatment with apoptotic but not necrotic cells, inhibits activation of IκB kinase (IKK) 
and downstream NF-κB. Notably, receptor tyrosine kinase Mer (MerTK) binding of AC is 
required for mediating this effect.  DC lacking MerTK expression (MerTKKD) or treated with 
blocking MerTK-specific Ab are resistant to AC-induced inhibition and continue to activate 
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NF-κB, and secrete proinflammatory cytokines. Blocking MerTK activation of the 
phosphatidylinositol 3-kinase (PI3K)/AKT pathway prevents AC-induced inhibition. These 
results demonstrate an essential role for MerTK-mediated regulation of the PI3K/AKT and 
NF-κB pathways in AC-induced inhibition of DC.  
 
 
Introduction 
    Dendritic cells (DC) are potent mediators of T cell activation and proinflammatory 
immune responses to foreign antigens and pathogens (Banchereau et al., 2000; Pulendran et 
al., 2001). However, DC also have an important role in maintaining immune homeostasis and 
tolerance to self-proteins (Hawiger et al., 2001; Scheinecker et al., 2002; Liu et al., 2002; 
Belz et al., 2002; Steinman et al., 2003). These two opposing functions are believed in part to 
reflect differences in DC activation, maturation, and/or subset. Tolerogenic DC typically 
exhibit an immature phenotype characterized by low cell surface expression of MHC and co-
stimulatory molecules, and do not secrete proinflammatory cytokines. Furthermore, soluble 
and cellular mediators that inhibit DC activation and maturation can establish a tolerogenic 
phenotype. For example, binding to and phagocytosis of apoptotic cells (AC) by immature 
DC inhibits activation and maturation induced by various stimuli (Sauter et al., 2000; Stuart 
et al., 2002). This inhibitory effect serves an important role since AC are present in tissues 
under both homeostatic and inflamed conditions, and provide a potential source of self-
proteins to mediate autoimmunity. Defective clearance of AC has been linked to different 
types of autoimmunity (Botto et al., 1998; O’Brien et al., 2002). A number of receptors 
expressed by immature DC such as the phosphatidylserine (PS) receptor, CD36, αvβ5 
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integrin and complement receptor C1qR are involved in AC binding and/or ingestion (Chen 
et al., 2004; Fadok et al., 2001; Savill et al., 2002; Roos et al., 2004). However, the relative 
contribution of these receptors in mediating the immunoregulatory effect(s) of AC on 
immature DC is unclear, and the molecular basis for this inhibition has not been defined in 
DC.  
    Recently, the Axl/Mer/Tyro3 receptor tyrosine kinase (RTK) family has been implicated in 
homeostatic regulation of antigen presenting cell (APC) activation (Lu and Lemke, 2001; 
Lemke and Lu, 2003). This family consisting of Axl, Tyro3 and MerTK is expressed by a 
variety of cell types including macrophages (Mφ) and DC. Mice lacking expression of all 
three RTKs exhibit hyperactivated Mφ and DC, which in turn drive lymphoproliferation and 
systemic autoimmunity (Lu and Lemke, 2001). Similarly, our group has shown that mice 
lacking MerTK expression (MerTKKD) develop lupus-like autoimmunity and are more prone 
to lipopolysaccharide (LPS)-induced endotoxic shock (Camenisch et al., 1999; Scott et al., 
2001; Cohen et al., 2002). Autoimmunity in MerTKKD mice correlates with a reduced rate of 
in vivo clearance of AC, which is consistent with findings that MerTK mediates AC 
phagocytosis by Mφ (Scott et al., 2001; Cohen et al., 2002). A ligand for MerTK is growth 
arrest specific gene (GAS) 6, which binds to PS expressed on the inverted plasma membrane 
of AC (Chen et al., 1997). Recognition of a GAS6-PS complex facilitates binding of AC and 
subsequent phagocytosis by Mφ. Accordingly, MerTK has been proposed to facilitate 
phagocytosis of AC and down-regulate activation in Mφ. Whether MerTK functions similarly 
in DC has yet to be determined. 
    We and others (Burkly et al., 1995; Rescigno et al., 1998; Wu et al., 1998; Weaver et al., 
2001; Ouaaz et al., 2002; Poligone et al., 2002) have demonstrated a key role for the 
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transcription factor NF-κB in regulating gene expression associated with the development, 
activation, maturation and APC function of DC. The NF-κB complex consists of homo- and 
heterodimers of the structurally related proteins p50, p52, p65 (RelA), c-Rel and RelB. NF-
κB is typically sequestered in the cytoplasm bound by the inhibitory molecules IκBα, IκBβ 
and IκBε (Baldwin, 1996; Ghosh et al., 1998; Ghosh and Karin, 2002). In response to a broad 
range of stimuli, including LPS and CD40 engagement, the multi-subunit complex IκB 
kinase (IKK) consisting of IKK1/IKKα, IKK2/IKKβ, and IKKγ/NEMO is activated upon 
phosphorylation (Delhase et al., 1999; Karin, 1999; Li et al., 1999; Tanaka et al., 1999). 
Activated IKK phosphorylates the IκB proteins, which in turn undergo polyubiquitination 
and subsequent degradation via the 26S proteasome (Ghosh et al., 1998; Ghosh and Karin 
2002). The latter permits nuclear translocation of NF-κB that binds to consensus sequences 
and induces gene transcription. We recently demonstrated that the immunosuppressive effect 
of IL-10 on DC maturation and APC function is mediated by inhibition of IKK activity and 
downstream NF-κB activation (Bhattacharyya et al., 2004) further arguing that the NF-κB 
pathway is a key target for immunoregulation of DC. In addition, IL-10-induced inhibition of 
DC was dependent on suppression of the phosphatidylinositol 3-kinase (PI3K)/AKT 
signaling pathway. Studies have shown that NF-κB activation can be regulated by the 
PI3K/AKT pathway via different mechanisms (Madrid et al., 2000; Guha and Mackman, 
2002; Martin et al., 2003; Gustin et al., 2004). 
    The current study was initiated to define the molecular basis of AC-induced inhibition of 
DC activation and effector function. Evidence is provided that AC inhibit activation of the 
NF-κB signaling pathway in DC, and that MerTK via PI3K/AKT signaling serves a major 
role in mediating this immunoregulatory effect.  
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Materials and methods 
Mice 
    NOD/LtJ. BALB/c and C57BL/6 (B6) mice were maintained and bred under specific-
pathogen free conditions. Establishment of MerTKKD mice has been described (Camenisch et 
al., 1999). Briefly, the tyrosine kinase domain of Mertk was replaced with a neomycin 
resistance gene, and B6.MerTKKD mice established. NOD MerTKKD mice were generated by 
breeding B6.MerTKKD and NOD mice, and then backcrossing the MertkKD gene onto the 
NOD genome for an additional 11 generations. At N11, Mouse MapPairs™ distinguishing 
B6, 129/Ola, and NOD/LtJ [Chr. 2 (D2Mit378, D2Mit94, D2Mit14, D2Mit393, D2Mit395, 
D2Mit190, D2Mit164, D2Mit256, D2Mit304, D2Mit224, D2Mit338, D2Mit307, D2Mit260, 
D2Mit309, D2Mit493, D2Mit451, D2Mit496, D2Mit287, D2Mit456, D2Mit265) 
(Invitrogen, Carlsbad, CA) were used in PCR according to the supplier’s directions to define 
a 17 cM segment derived from 129/Ola and containing MertkKD. Use of mice was approved 
by the Institutional Animal Care and Use Committee of the University of North Carolina at 
Chapel Hill.  
 
Preparation of DC 
    Bone marrow-derived DC (BMDC) and splenic DC (sDC) were prepared from male or 
female mice between 8-12 weeks as described (Bhatacharyya et al., 2004).  
 
Flow cytometry 
    The following monoclonal Abs used for fluorescence staining were purchased from BD 
PharMingen (San Diego, CA): FITC-αCD40, FITC-αCD86, FITC-αCD80, PE-αCD11c, PE-
 142
αH2Kd and PE-αCD11b. PE-αmouse IgG, FITC-αmouse IgG and streptavidin-PE were also 
purchased from BD PharMingen. Polyclonal goat-αMerTK, and normal goat IgG were 
purchased from R&D Systems and biotin-αgoat IgG was purchased from Vector. Stained 
cells were analyzed on a FACSCalibur (BD Biosciences, San Jose, CA) using Summit 
Software (Cytomation, Ft. Collins, CO). 
 
DC pretreatment with AC, necrotic cells, or PI3K inhibitors. 
    Thymocytes prepared from 4-6 week old mice, were adhered to plastic for 2 hr to remove 
APC, irradiated at 600R and then cultured in base medium for 12 hr. Flow cytometry 
demonstrated  >95% apoptotic and <1% necrotic thymocytes based on Annexin-V and 
propidium iodide staining. Apoptosis was confirmed via DNA fragmentation analysis. DC 
were co-cultured with AC at a ratio of 1:5 (DC:AC) for indicated times. For necrotic cell 
preparations, thymocytes were frozen at -80oC and thawed for 4 cycles, and then co-cultured 
with DC at a 5:1 ratio (necrotic cell:DC equivalence) for 3 hr. Following pretreatment with 
AC or necrotic cells, DC were resuspended accordingly, and stimulated with LPS. 
    In some experiments, DC were treated with αMerTK Ab prior to AC incubation. Briefly, 
DC (5x106/well) were incubated with αmouse FcγIII/II (BD PharMingen) in 6-well ultra-low 
cluster plates for 0.5 hr at 37oC to block Fc receptor binding. DC were then treated for 1 hr at 
37oC with 20 µg/ml of either goat αMerTK Ab (AF591, R&D Systems, Inc., Minneapolis, 
MN) or goat IgG (R&D Systems), an isotype control. 
    Alternatively, DC (5x106 cells/well) were treated with wortmannin (200 nM) or Ly294002 
(50 µM) (Cell Signaling TechnologyTM, Beverly, MA) for 1 hr prior to AC treatment or LPS 
stimulation as described (Bhatacharyya et al., 2004).   
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EMSA and Western blotting 
    Nuclear and cytoplasmic extracts were prepared from DC as described (Beg et al., 1993). 
EMSA was performed using 32P-labeled DNA probes containing NF-κB binding sites derived 
from MHC class I   H2K promoter:  
5’-CAGGCTGGGGATTCCCATCTCCACAGTTTCACTTC-3’ (Weaver et al., 2001). A 
double stranded OCT-1 DNA probe:  5’-TGTCGAATGCAAATCACTAGAA-3’ was used 
as control. Bands were visualized using a phosphoimager (Molecular Dynamics, Sunnyvale, 
CA). For each treatment at least three EMSAs were run. 
    Western blotting was carried out as described (Bhatacharyya et al., 2004). Membranes 
were probed with Abs specific for: IκBα, IκBβ, IκBε, IKK1, ERK1, and ERK2 (Santa Cruz 
Biotechnology, Santa Cruz, CA); IKK2, pIκBα, pIKK1 (Ser180)/pIKK2 (Ser181), pAKT 
(Thr308), AKT, pSAPK/JNK (Thr183/Tyr185), SAPK/JNK, phospho-p38MAPK 
(Thr180/Tyr182), p38MAPK, pERK1/pERK2 (Thr202/Tyr204), and phospho-tyrosine (Cell 
Signaling TechnologyTM); MerTK (R&D Systems);  β-actin (Sigma, St. Louis, MO). Binding 
of secondary HRP-labeled goat-αrabbit, donkey-αgoat or goat-αmouse Abs (Santa Cruz 
Biotechnology) was analyzed using SuperSignal® West Pico or West Dura 
Chemiluminescent Substrate (Pierce, Rockland, IL). 
 
IKK Assay 
    IKK signalosome was immunoprecipitated from 700 µg of a whole DC lysate using 
Protein G agarose beads (Upstate, Lake Placid, NY) and rabbit polyclonal αIKK1 as per the 
manufacturer’s instruction. In vitro kinase reaction was performed by incubating the IKK 
signalosome-bead complex with IκBα-GST and 20 µl of a magnesium/ATP cocktail 
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(Upstate) for 60 min at 30oC in kinase buffer. Supernatants were collected and kinase activity 
determined by measuring phosphorylation of the IκBα-GST substrate via immunoblot probed 
with αpIκBα Ab. 
 
AKT kinase assay 
    DC (5x106) were stimulated as described above and whole cell lysates prepared. AKT 
kinase activity was determined using an AKT kinase assay kit (Cell Signaling Technology). 
Briefly, AKT was immunoprecipitated according to the manufacturer’s instructions, and 
kinase activity assessed by measuring phosphorylation of a GSK3 substrate via immunoblot 
using αpGSK3 Ab. 
 
Immunoprecipitation of MerTK 
    Whole cell lysates prepared from DC (5x106) were pre-cleared with protein G sepharose 
beads, and MerTK immunopreciptated using Protein G sepharose beads precoated with 
αMerTK Ab. For “pull-down” experiments, DC (107) were treated with AC (1:5) for varying 
times, chilled on ice, resuspended in 1 ml of the cell-permeable protein cross-linker dimethyl 
3,3’-dithiopropionimidate dihydrochloride (Sigma) in PBS (2 mg/ml), and incubated at room 
tempertature for 20 min. A whole cell lysate was prepared and MerTK immunoprecipitated 
as above. In some experiments, Western blots were probed with Ab specific for the PI3K 
subunits p85α, p110α (Cell Signaling TechnologyTM), p110β, p110δ (Santa Cruz 
Biotechnology) or Axl (R&D Systems) and Tyro3 (BD PharMingen) specific Ab. 
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Measurement of TNFα production from DC 
    DC (9x105/well) were pretreated with or without AC for 3 hr, washed and then stimulated 
with LPS for 48 hr. Supernatants were collected and assayed for TNFα in triplicate using an 
ELISA kit (BD PharMingen) following the manufacturer’s instructions.  
 
 
Results 
NF-κB activation is inhibited in DC by AC pretreatment. 
    Binding of AC by immature DC impairs subsequent activation, maturation, and APC 
function (Sauter et al., 2000; Stuart et al., 2002).  Since these events are largely regulated by 
NF-κB, the effect of AC on the NF-κB signaling pathway was investigated. For this purpose, 
NOD BMDC which are CD11b+CD8α- and exhibit an immature phenotype (CD40lo, CD80lo, 
CD86lo) (Weaver et al., 2001) were examined. BMDC were pretreated at a ratio of 1:5 with 
AC for varying times, stimulated with LPS (50 ng/ml) for 0.5 hr, and nuclear NF-κB DNA 
binding activity assessed via EMSA. BMDC treated with LPS-only exhibited a 5.7-fold 
increase in NF-κB DNA binding relative to untreated BMDC (Figure 1A). In contrast, AC 
pretreatment resulted in a temporal loss of LPS-stimulated NF-κB DNA binding, which was 
completely inhibited after a 3 hr incubation with AC (Figure 1A). No effect on DNA binding 
of OCT-1 was detected, indicating that the inhibitory effect of AC was NF-κB-specific 
(Figure 1A). Titrating AC showed that 1:5 BMDC to AC was the lowest ratio at which 
maximum suppression of NF-κB activity induced by LPS (50 and 500 ng/ml) was observed 
(data not shown). This ratio was used for all subsequent experiments.  Analogous to BMDC, 
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a reduction (~5-fold) in LPS-stimulated nuclear NF-κB activity was detected in NOD DC 
prepared from the spleen (sDC), and pretreated with AC (Figure 1B). Inhibition of NF-κB 
activity was specific for AC. For example, LPS-stimulated NF-κB DNA binding was 
unaffected by pretreatment of BMDC with either necrotic cells or polystyrene latex beads 
(Figure 1C). Furthermore, de novo protein synthesis was required for AC-induced inhibition. 
Despite AC pretreatment, LPS-stimulated NF-κB activation was readily detected in BMDC 
incubated with 10 µg/ml cyclohexamide (Figure 1D). 
    In agreement with the above EMSA data, LPS-stimulated degradation of IκBα, IκBβ, and 
IκBε in BMDC was progressively inhibited with increasing times of AC pretreatment (Figure 
2A). Furthermore, inhibition of LPS-induced IκB degradation by AC pretreatment coincided 
with a reduction in IκBα phosphorylation (Figure 2B). IκBα degradation stimulated by LPS 
was also inhibited in sDC pretreated with AC for 3 hr (Figure 2C). 
    The lack of LPS-induced IκB degradation suggested that upstream IKK activity was 
inhibited by AC pretreatment. To test this possibility, BMDC were pretreated with AC for 
0.5 or 3 hr and stimulated with LPS for 15 min. Temporal analyses demonstrated that 
maximum IKK activity in BMDC was detected after a 15 min incubation with LPS (data not 
shown). Cytoplasmic extracts were prepared, the IKK signalosome immunoprecipitated and 
kinase activity of the complex determined by measuring phosphorylation of an IκBα-GST 
substrate in vitro. Phosphorylation of the IκBα-GST substrate was readily detected in LPS-
stimulated versus untreated BMDC (Figure 2D).  In comparison, when LPS-stimulated 
BMDC where pretreated with AC for 0.5 and 3 hr, phosphorylation of the IκBα-GST 
substrate was reduced 6.8- and 54-fold, respectively (Figure 2D). No significant difference 
was detected in the amount of IKK1 and IKK2 protein in the respective BMDC lysates 
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(Figure 2D), indicating that the lack of in vitro phosphorylation of the IκBα-GST substrate 
was due to reduced IKK activity and not inefficient immunoprecipitation of the IKK 
complex.  
    AC pretreatment of DC had no significant effect on LPS-stimulated activation of the 
mitogen-activated protein kinase (MAPK) pathway. LPS-stimulated phosphorylation of JNK, 
ERK1/2 and p38 MAPK was unaffected by AC pretreatment (Figure 2E-G).  These data 
demonstrate that AC pretreatment of either BMDC or sDC results in inhibition of IKK 
signalosome activation, downstream phosphorylation and degradation of the IκB proteins, 
and NF-κB DNA binding activity induced by LPS stimulation. Furthermore, AC pretreatment 
selectively inhibits LPS-induced NF-κB signaling.   
 
MerTK is required to mediate AC-induced inhibition of NF-κB activation in DC. 
    MerTK is necessary for efficient phagocytosis of AC by Mφ, and is associated with down-
regulation of Mφ activation (Lu and Lemke, 2001; Camenisch et al., 1999; Scott et al., 2001; 
Hu et al., 2004; Todt et al., 2004). Whether MerTK mediates AC-induced inhibition of NF-
κB activity in DC was therefore investigated. DC which lack MerTK expression were 
prepared from NOD mice homozygous for the MertkKD null mutation (NOD.MerTKKD), and 
the effect of AC pretreatment on LPS-stimulated NF-κB activation determined.  Whereas 
NF-κB DNA binding was inhibited in NOD BMDC, pretreatment with AC had no significant 
effect on the induction of NF-κB activity in NOD.MerTKKD BMDC stimulated with LPS 
(Figure 3A). LPS-induced NF-κB DNA binding was also unaffected by AC pretreatment in 
NOD.MerTKKD sDC (Figure 3D).  
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    Analyses of IκB protein degradation and IKK activity confirmed that AC failed to inhibit 
NF-κB activity in NOD.MerTKKD DC. Degradation of the IκB proteins was observed in 
NOD.MerTKKD but not NOD BMDC or sDC pretreated with AC and stimulated with LPS 
(Figures 3B,E). Furthermore, pretreatment with AC failed to inhibit in vitro IKK activity in 
lysates prepared from NOD.MerTKKD but not NOD BMDC (Figure 3C). Similarly, LPS-
stimulated IKK activation as measured by phosphorylation of IKK1 and IKK2 was 
unaffected by AC pretreatment in NOD.MerTKKD sDC, but was significantly reduced in 
NOD sDC (Figure 3F). Moreover, AC failed to inhibit NF-κB DNA binding and 
phosphorylation of IKK in LPS-stimulated BMDC prepared from B6 mice lacking MerTK 
(B6.MerTKKD) (Figure 8), demonstrating that the inability of AC to block NF-κB activation 
in NOD.MerTKKD DC was not intrinsic to the NOD genotype.  
    To confirm the role of MerTK in AC-induced inhibition of NF-κB activity, the effect of 
treating wild-type DC with a blocking αMerTK Ab was investigated. BMDC were treated 
with either αMerTK or isotype control Abs, incubated with AC for 3 hr, and then stimulated 
with LPS. LPS-induced NF-κB DNA binding was efficiently inhibited in BMDC treated with 
the isotype control Ab and AC (Figure 4A). In contrast, LPS-induced NF-κB DNA binding 
was readily detected in BMDC treated with the αMerTK Ab despite AC pretreatment (Figure 
4A). Furthermore, AC failed to block LPS-induced degradation of the IκB proteins in DC 
treated with αMerTK but not isotype control Abs (Figure 4B).  The effect of MerTK Ab 
blocking on AC-induced inhibition of NF-κB signaling was also detected in BMDC cultured 
from BALB/c.   Whereas AC inhibited LPS-induced NF-κB DNA binding and IκB protein 
degradation in BALB/c BMDC treated with the isotype control Ab, αMerTK Ab blocked this 
effect (Figure 4C,D). Collectively, these results demonstrate that MerTK signaling is 
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necessary to mediate AC-induced inhibition of the NF-κB pathway, independent of the 
genotype of the DC.   
 
AC-induced inhibition of NF-κB activation is mediated through the PI3K/AKT pathway 
in DC. 
    Signaling via a MerTK chimeric molecule or MerTK activates the PI3K/AKT pathway in 
32D transfectant cells and retinal pigment epithelial cells, respectively (Guttridge et al., 
2002; Hall et al., 2003). In addition, the PI3K/AKT pathway negatively regulates NF-κB 
activation in human monocytes (Guha and Mackman, 2002). Accordingly, a role for the 
PI3K/AKT pathway in mediating AC-induced inhibition of NF-κB activation was assessed. 
Initially, AKT kinase activity was measured in lysates prepared from NOD BMDC treated 
with AC.  AC treatment induced a 3-fold increase in AKT kinase activity relative to 
untreated NOD BMDC (Figure 5A). Furthermore, pretreatment of DC with the PI3K 
inhibitors wortmannin (Wort) or LY294002 (LY) for 1 hr effectively blocked AC-induced 
AKT kinase activity (Figure 5A).  Importantly, AC treatment failed to induce AKT kinase 
activity in NOD.MerTKKD BMDC (Figure 5A).  In addition, phosphorylation of AKT 
induced by AC (Figure 5B) was blocked by αMerTK but not isotype Ab treatment. 
    Next, the effect of Wort or LY pretreatment on AC-induced inhibition of NF-κB activation 
was determined. Whereas AC blocked LPS-stimulated nuclear NF-κB DNA binding, NF-κB 
activation was readily detected in NOD BMDC pretreated with Wort or LY and then 
incubated with AC (Figure 5C). In addition, AC failed to inhibit LPS-stimulated IκB protein 
degradation (Figure 5E) and IKK activity (Figure 5G) in NOD BMDC treated with Wort or 
LY. The two PI3K inhibitors similarly prevented AC-induced inhibition of nuclear NF-κB 
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DNA binding activity and degradation of the IκBs in NOD sDC (Figure 5D,F) or BALB/c 
BMDC (Figure 9) stimulated with LPS.  
    The intra-cytoplasmic domain of MerTK contains a PI3K binding motif (YDIM). To 
determine whether PI3K is directly associated with MerTK, NOD BMDC were treated with 
AC and proteins chemically cross-linked. MerTK was then immunoprecipitated and the 
resulting complexes analyzed via Western blot. MerTK but not p85α/PI3K was detected in 
untreated NOD BMDC (Figure 6A). In contrast, a temporal increase in p85α/PI3K was seen 
in AC-treated NOD BMDC, with no significant change in the level of MerTK (Figure 6A).  
Furthermore, the PI3K catalytic subunit p110δ, but not p110α or p110β was found complexed 
with immunoprecipitated MerTK (Figure 6B). These results demonstrate that AC-induced 
inhibition of NF-κB signaling is dependent on MerTK activation of the PI3K/AKT pathway. 
 
AC-induced inhibition of DC maturation is mediated by MerTK and PI3K/AKT 
signaling.  
    The role of MerTK and PI3K/AKT signaling in AC-induced inhibition of DC maturation, 
as determined by TNFα secretion, was investigated. Initially, NOD and NOD.MerTKKD 
BMDC were compared. As demonstrated in Figure 7A NOD and NOD.MerTKKD BMDC 
secreted similar levels of TNFα upon LPS stimulation. However, AC pretreatment 
significantly inhibited LPS-stimulated TNFα secretion by NOD BMDC (p<10-3), whereas 
NOD.MerTKKD BMDC continued to produce TNFα (Figure 7A). Secretion of TGFβ and IL-
10 was not detected in either NOD or NOD.MerTKKD BMDC following pretreatment with 
AC (data not shown).  Furthermore, LPS-stimulated TNFα secretion was significantly 
increased in cultures of NOD BMDC pretreated with Wort or LY plus AC relative to cultures 
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treated with AC alone (P<10-3) (Figure 7B). These data demonstrate that AC inhibition of 
DC maturation is mediated by MerTK and PI3K/AKT signaling. 
 
 
Discussion 
    DC are key contributors to the establishment and maintenance of peripheral tolerance to 
self. Furthermore, AC are believed to have an important role in establishing “tolerogenic” 
DC in vivo (Scheinecker et al., 2002; Liu et al., 2002). The latter is supported by reports 
demonstrating the potent inhibitory properties of AC on DC in vitro (Sauter et al., 2000; 
Stuart et al., 2002; Ip and Lau, 2004). However, the molecular basis for AC-induced 
inhibition of DC is ill-defined. Here we have identified critical signaling pathways targeted in 
DC upon binding of AC, and the key receptor mediating this inhibitory effect is MerTK. 
    Pretreatment with AC blocked activation of the NF-κB signaling pathway in both BMDC 
and sDC. This effect was marked by inhibition of LPS-induced IKK activation as measured 
by in vitro kinase activity or phosphorylation of IKK1 and IKK2 (Figures 2,3). Consistent 
with inhibition of the IKK complex was the lack of downstream IκB protein phosphorylation 
and degradation, and NF-κB nuclear translocation and DNA binding  following LPS 
stimulation of DC pretreated with AC (Figures 1-3). In addition, NF-κB activation induced 
by CD40 crosslinking was inhibited (Figure 10), indicating that AC block multiple pathways 
that engage NF-κB. Blockade of NF-κB signaling was seen only by AC pretreatment.  
Incubation with necrotic cells or phagocytosis of latex beads had no significant effect on 
LPS-induced NF-κB activation (Figure 1C). Furthermore, the inhibitory effect of AC showed 
selectivity among LPS-induced pathways; in this case the activation of NF-κB.  For example, 
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LPS-stimulated phosphorylation of the MAPK molecules JNK, ERK1/2 and p38 MAPK was 
unaltered by AC pretreatment (Figure 2E-G). This observation further supports the 
hypothesis that blockade of NF-κB activation is essential for promoting AC-mediated DC 
suppression. Indeed, the effects of AC can be mimicked by gene transfer of a modified IκBα 
recombinant that specifically inhibits NF-κB activation, and alone is sufficient to prevent up-
regulation of co-stimulatory molecule expression, proinflammatory cytokine secretion and T 
cell stimulation by immature DC (Weaver et al., 2001; Ouaaz et al., 2002; Poligone et al., 
2002; Hackstein et al., 2001). Interestingly, inhibition of NF-κB signaling by AC appears to 
be DC-specific. In Mφ, pro-inflammatory responses are down-regulated by AC pretreatment 
yet NF-κB activation is still inducible (McDonald et al., 1999; Cvetanovic and Ucker, 2004). 
This disparity may reflect the relative importance of the NF-κB pathway in regulating 
activation and the effector functions of DC versus Mφ.  
    The second important observation made in this study is that MerTK is required for AC-
induced inhibition of DC. This was shown in both genetic and specific Ab blocking 
experiments. First, AC pretreatment of NOD.MerTKKD BMDC or sDC failed to establish a 
tolerogenic phenotype seen in MerTK-expressing DC. Despite AC pretreatment, NF-κB 
signaling was readily induced in NOD.MerTKKD DC, which correlated with continued APC 
function (Figures 3,7). Second, the inability of AC to inhibit NF-κB activation was also 
observed when wild-type NOD or BALB/c DC were treated with αMerTK Ab to block 
MerTK binding of AC (Figure 4). The αMerTK Ab inhibits signaling by preventing AC-
induced phosphorylation of MerTK tyrosine residues (Y.H. and R.T., unpublished results).  
The failure of AC to inhibit NOD.MerTKKD DC therefore was due to the lack of MerTK 
expression and not a secondary defect. One possibility is that family members Axl and Tyro3 
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are also involved in AC-induced inhibition. For example, AC may bind a heterodimeric 
complex consisting of MerTK and Axl and/or Tyro3, and in turn the absence of MerTK 
expression or blocking MerTK activation with Ab may disrupt such a complex. However, 
this scenario is unlikely since neither Axl nor Tyro3 were co-immunoprecipitated with 
MerTK prepared from chemically cross-linked lysates of AC pretreated NOD BMDC (Figure 
11).  
    Another key finding is that AC-induced inhibition of DC is dependent on MerTK 
activation of the PI3K/AKT pathway. AC treatment elicited AKT kinase activity in NOD but 
not NOD.MerTKKD BMDC (Figure 5A). A role for PI3K/AKT signaling was demonstrated 
by the use of Wort and LY, which effectively blocked the capacity of AC to inhibit NF-κB 
signaling and DC maturation (Figures 5,7B). The latter was observed by measuring TNFα 
secretion, although the capacity of AC to inhibit upregulation of CD40, CD80 and CD86 
expression following LPS stimulation was also blocked by the PI3K inhibitors (Figure 12). 
These results are consistent with a consensus PI3K docking site located in the MerTK intra-
cytoplasmic domain, and detection of a p85α/p110δ complex associated with MerTK 
following AC incubation (Figure 6). How PI3K/AKT signaling blocks downstream 
activation of the IKK signalsome is currently under investigation. The fact that 
cyclohexamide pretreatment of BMDC blocked AC-induced inhibition of NF-κB activation 
(Figure 1D), suggests that PI3K/AKT signaling mediates downstream de novo protein 
synthesis of regulatory molecules. Preliminary findings suggest that LPS-stimulated 
activation of transforming growth factor β-activated kinase 1 (TAK1) is unaffected by AC 
pretreatment (Z.Y. and R.T., unpublished results). TAK1 is activated by interacting with 
tumor necrosis factor receptor-associated factor 6 (Ninomiya et al., 1999), suggesting that 
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events downstream of this complex are targeted by AC pretreatment. Although other 
molecules (and pathways) such as phosphatidylinositol-specific phospholipase Cγ2 (Todt et 
al., 2004) and the guanine exchange factor Vav1 (Mahajan and Earp, 2003) may be involved 
in MerTK signaling, inhibition of the PI3K/AKT pathway in DC is nevertheless sufficient to 
block the effects of AC. A chimeric molecule containing the intracellular domain of MerTK 
has been reported to activate both PI3K/AKT and NF-κB pathways in pro-B cell transfectants 
(Georgescu et al., 1999). This finding coupled with our own suggests that the nature of 
MerTK signaling is cell-dependent. It is also noteworthy that induction of the PI3K/AKT 
pathway in DC can either inhibit (Figure 5) or promote activation of the NF-κB pathway 
(Bhattacharyya et al., 2004; Yu et al., 2004). Distinct effects of PI3K/AKT signaling may 
reflect the subunit composition of the PI3K heterodimer and/or the isoform of AKT. Fukao et 
al. reported that the inhibitory effect of PI3K on LPS-stimulated activation of p38MAPK in 
DC is mediated by a p85α/p110β complex (Fukao et al., 2002). In contrast, AC induction of a 
p85α/p110δ complex appears to have no effect on LPS-stimulated p38MAPK activation 
(Figure 2G). Finally, activation of other signaling events engaged by a given receptor may 
alter the “context” and in turn the downstream effect(s) of the PI3K/AKT pathway. 
    An essential role for MerTK in efficient phagocytosis of AC by Mφ has been previously 
demonstrated (Scott et al., 2001; Cohen et al., 2002). In contrast, Cohen and colleagues 
demonstrated unaltered AC phagocytosis by B6.MerTKKD BMDC (Behrens et al., 2003) 
suggesting that the primary function of MerTK is to transduce inhibitory signals upon 
binding of AC. Importantly, the role of MerTK in regulating DC activation and function is 
AC-dependent. No significant differences were observed between NOD and NOD.MerTKKD  
DC in NF-κB signaling or TNFα secretion when AC pretreatment was not included, and DC 
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were stimulated with LPS-only (Figures 3,7A). A number of DC subsets have been defined, 
and whether MerTK serves the same function among different DC is of interest. For 
example, the relative contribution of different receptors for AC may vary depending on the 
subset of DC, and the nature and concentration of the corresponding ligand. However, the 
fact that the lack of expression and/or blocking of MerTK efficiently inhibited the effects of 
AC on NOD, BALB/c and B6 BMDC and/or sDC strongly argues that this RTK plays a 
major role in regulating DC activation and maturation. Potential defects in MerTK function 
may in turn contribute to autoimmunity. 
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Figure 1 
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Pretreatment of DC with AC inhibits DNA binding activity of NF-κB. NOD BMDC (A) 
or sDC (B) were pretreated with AC at a ratio of 1:5 (DC to AC) for the indicated times or 
left untreated, and then stimulated with LPS (50 ng/ml) for 0.5 hr. Nuclear NF-κB DNA 
binding was measured via EMSA. Composition of NF-κB complexes was previously 
determined via super-shift analysis.  A double stranded OCT-1 DNA probe was used as an 
internal control. Densitometric analyses represent the ratio of intensity of NF-κB to OCT-1 
binding per unit area and are represented as arbitrary units for the respective EMSAs. (C) 
Nuclear NF-κB binding activity was measured in NOD BMDC pretreated with AC, 
polystyrene latex beads (LB), or necrotic cells (NC) for specified times or left untreated, and 
then stimulated with LPS for 0.5 hr. (D) NOD BMDC were preincubated with 
cyclohexamide (10 µg/ml) (CH) for 15 min, treated with AC for 3 hr, stimulated with LPS 
(50 ng/ml) for 0.5 hr and nuclear NF-κB DNA binding activity determined. Data are 
representative of three independent experiments.  
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Figure 2 
 
 
 
AC pretreatment inhibits IκB protein degradation and IKK activity.  NOD BMDC (A, 
B, D, E-G) or sDC (C) were pretreated with AC and stimulated with LPS as in Figure 
Legend 1. (A, C) Cytoplasmic IκBα, IκBβ, IκBε, and β-actin protein was detected by Western 
using the same blot. Densitometric readings represent the ratio of intensity of IκB protein to 
β-actin expression per unit area, and are represented as an arbitrary unit. (B) Expression of 
phospho (P)-IκBα in cytoplasmic extract was determined by Western blot. Densitometric 
analysis represents the ratio of intensity of phospho-IκBα to β-actin expression per unit area. 
(D) In vitro IKK activity was determined by measuring phosphorylation of an IκBα−GST 
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substrate. Densitometric analysis represents the intensity of phosphorylated (P) IκBα-GST in 
arbitrary units.  The amount of IKK1 and IKK2 immunoprecipitated in the samples was 
analyzed by Western blot. Western blot was used to detect (E) phospho-JNK versus JNK, (F) 
phospho-ERK versus ERK and (G) phospho-p38MAPK versus p38MAPK in whole cell 
lysates.Data are representative of three independent experiments. 
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Figure 3 
 
 
 
 
Pretreatment with AC inhibits NF-κB and IKK activation in NOD but not 
NOD.MerTKKD DC. NOD and NOD.MerTKKD BMDC (A-C) or sDC (D-F) were pretreated 
with AC and stimulated with LPS as in Figure Legend 1. (A, D) DNA binding activity of 
nuclear NF-κB or OCT-1 was determined via EMSA. (B, E) Cytoplasmic 
 161
IκBα, IκBβ, IκBε and β-actin protein was detected via Western using the same blot. (C) In 
vitro IKK activity and IKK1 and IKK2 protein expression were determined as in Figure 
Legend 2. (F) IKK phosphorylation was detected via Western, and the same blot reprobed to 
for IKK1 and IKK2 protein. Data are representative of three independent experiments. 
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Figure 4 
 
 
 
αMerTK Ab blocks AC-mediated inhibition of NF-κB activation in NOD and BALB/c 
DC. NOD (A, B) or BALB/c (C, D) BMDC were pretreated with 20 µg/ml of αMerTK or 
isotype control Ab. BMDC were then treated with AC and stimulated with LPS as in Figure 
Legend 1. (A, C) EMSA was used to measure DNA binding activity of nuclear NF-κB or 
OCT-1. (B, D) Cytoplasmic IκBα, IκBβ, IκBε and β-actin was detected via Western with the 
same blot. Data are representative of three independent experiments. 
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Figure 5 
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The PI3K/AKT pathway mediates AC-induced inhibition of NF-κB activation in NOD 
DC. NOD or NOD.MerTKKD BMDC (A-C,E,G) and sDC (D,F) were incubated with 200 nM 
Wort or 50 µM LY for 1 hr, and then treated with AC for 3 hr or left untreated. In some 
experiments (C-G), DC were subsequently stimulated with LPS (50 ng/ml) for 0.5 hr. (A) In 
vitro AKT activity was determined by measuring phosphorylation of a GSK3 substrate by 
Western blot. The same blot was reprobed for AKT protein. (B) NOD BMDC were 
pretreated either with isotype control or αMerTK Abs for 1 hr and then incubated with AC at 
specified times. Phosphorylation of AKT in cytoplasmic extracts was determined via 
Western blot using an αphospho AKT Ab. The same blot was reprobed for AKT protein. (C, 
D) Nuclear NF-κB or OCT-1 DNA binding activity was determined via EMSA. (E, F) 
Cytoplasmic IκBs and β-actin protein were detected by Western using the same blot. (G) In 
vitro IKK activity was measured as in Figure Legend 2. The same blot was reprobed for 
IKK1 and IKK2 protein. Data are representative of three independent experiments. 
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Figure 6 
 
 
 
A PI3K p85α/p100δ complex is associated with MerTK upon AC pretreatment of NOD 
BMDC. MerTK was immunoprecipitated with αMerTK Ab from total cell lysates prepared 
from NOD BMDC pretreated with AC at specified times (A) or for 30 min (B) or not (Cont). 
Western blots were probed for p85α/PI3K, MerTK (A, B), and p110α, p110β, and p110δ (B) 
using the same membranes. 
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Figure 7 
 
 
 
AC-induced inhibition of TNFα secretion by NOD DC is mediated by MerTK-
dependent PI3K signaling. (A) NOD and NOD.MerTKKD BMDC were pretreated with AC 
for 3 hr, stimulated with LPS as in Figure Legend 1, and TNFα secretion measured via 
ELISA. (B) NOD BMDC were incubated with 200 nM Wort or 50 µM LY for 1 hr, treated 
with AC and LPS, and TNFα secretion measured as above. 
 
 167
Figure 8 
 
 
 
 
AC pretreatment inhibits NF-κB and IKK activation in B6 but not B6.MerTKKD 
BMDC. B6 or B6.MerTKKD BMDC were pretreated with AC for 3hr and then stimulated 
with LPS as in Figure Legend 1. (A) DNA binding activity of nuclear NF-κB or OCT-1 was 
determined via EMSA. (B) Phospho-IKK1 and -IKK2 were detected by Western and the 
same blot reprobed for IKK1 and IKK2 protein. Data are representative of three independent 
experiments. 
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Figure 9 
 
 
 
Pretreatment with PI3K inhibitors blocks AC-induced inhibition of NF-κB activation in 
BALB/c BMDC. BALB/c BMDC were preincubated with Wort (200 nM) or LY (50 µM) for 
1 hr, treated with AC for 3 hr or left untreated, and then stimulated with LPS (50 ng/ml) for 
0.5 hr. (A) Nuclear NF-κB or OCT-1 DNA binding activity was determined via EMSA. (B) 
Cytoplasmic IκBα protein was assessed via Western and the same blot reprobed for β-actin 
protein. 
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Figure 10 
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Pretreatment with AC inhibits αCD40 Ab induced NF-κB activation and IκBα 
degradation in NOD but not NOD.MerTKKD DC. NOD and NOD.MerTKKD BMDC were 
pretreated with AC for indicated times or left untreated, and then stimulated with 10 µg/ml of 
hamster-αCD40 (clone HM40-3) and 20 µg/ml αhamster (clone G188-2) Abs for 1 hr. (A) 
DNA binding activity of nuclear NF-κB or OCT1 was determined via EMSA. (B) Expression 
of cytoplasmic IκBα  was analyzed by Western and the same blot reprobed for β-actin. 
Corresponding densitometric analysis represents the ratio of intensity of IκBα expression to 
β-actin expression per unit area. 
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Figure 11 
 
 
 
Axl and Tyro3 are not associated with immunoprecipitated MerTK. NOD BMDC were 
pretreated with AC and MerTK immunoprecipitated (IP) with αMerTK Ab. Western blot was 
used to detect MerTK, Axl, and Tyro3 by reprobing the same membrane.  Alternatively, 
whole cell extracts prepared from AC-pretreated NOD BMDC (WCE) or NOD thymocytes 
(THY; negative control) were similarly analyzed.  
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Figure 12 
 
 
 
AC-induced inhibition of NOD DC activation is mediated by PI3K signaling. NOD 
BMDC were preincubated with 200 nM Wort or 50 µM LY and treated with AC or left 
untreated. DC surface phenotype was determined via flow cytometry 24 hr +/- LPS (100 
ng/ml) stimulation. Open and shaded histograms represent untreated versus LPS-treated cells 
NOD BMDC, respectively.  
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